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ABSTRACT
Gastrointestinal tract disease is the leading natural cause of death in horses and
horses with ischemic intestinal disease have the greatest mortality. We hypothesized there
is basal synthesis of endothelin-1 (ET-1) in the intestinal tract of healthy horses that is
likely involved in regulating vasomotor tone, secretion and motility and that ET-1
synthesis increases with gastrointestinal tract disease, which may be involved in the
pathophysiology of these disorders.
Plasma ET-like immunoreactivity was increased in horses with naturally-acquired
gastrointestinal disease, compared with normal horses; values were greatest in horses
with large intestinal strangulation obstruction, enterocolitis and peritonitis. There was an
association between ET-1 levels and survival, PCV and duration of signs of pain.
Immunohistochemical staining for ET-1 was present in surface epithelium, villi,
muscularis and serosa of numerous intestinal segments in healthy horses. Staining was
also present in submucosal vessels with veins staining more intense than arteries.
Staining appeared more diffuse and intense in samples from horses with intestinal
strangulation obstruction. Polymerase chain reaction analysis revealed the presence of
ET-1 gene expression in numerous intestinal segments of normal horses. These findings
suggest ET-1 is involved in physiologic functions such as regulation of secretion,
vasomotor tone and motility, and that increased ET-1 with strangulation obstruction may
be involved in the pathophysiology of these disorders.
ET-1 caused sustained, concentration-dependent increases in cecal longitudinal
smooth muscle tone in vitro, but the magnitude of contraction was less than that induced
by carbachol. Pre-incubation of tissues with ETA (BQ-123) and ETB (IRL-1038) receptor

xiii

antagonists alone did not inhibit ET-1 induced contraction. However, contractile
responses were inhibited when tissues were incubated with both antagonists (10-5 M)
together, suggesting both ETA and ETB receptors mediate the contraction. Electric field
stimulation did not change the contractile response.
These studies indicate a physiologic role of ET-1 in the equine gastrointestinal
tract and that increased synthesis and release occurs with gastrointestinal tract disease,
especially ischemic conditions, and may contribute to the pathophysiology of these
disorders. Further studies involving ET-1 and ET antagonists appear warranted.

xiv

CHAPTER 1
INTRODUCTION

1

Endothelin (ET), a potent vasoconstrictor, was first discovered in cultured porcine
aortic endothelial cells. Since its discovery, numerous studies of the role of ET in various
diseases have been conducted. Endothelin is synthesized in a variety of tissues and cell
types, including endothelial cells, macrophages, mesangial cells, mast cells and
astrocytes, where they modulate vasomotor tone, cell proliferation and hormone
synthesis. Endothelin regulates blood flow in association with endothelium-derived nitric
oxide (NO). Endothelin is also proposed to be an excitatory component of the nonadrenergic, non-cholinergic innervation (NANC) of the enteric nervous system
controlling gastrointestinal smooth muscle motility in conjunction with NO, an inhibitory
component of the NANC system.
Endothelins are a family of vasoactive peptides that have potent vasoconstrictor
actions. Of the three isoforms (ET-1, ET-2 and ET-3), ET-1 is implicated in the majority
of physiological and pathological functions. Endothelin exerts its biologic activity by
binding to its specific G-protein linked receptors, ETA and ETB. The ETA receptors are
located on the vascular smooth muscle cells and binding of ET to ETA receptors mediates
vasoconstriction. The ETB receptors are located on endothelial cells and in non-vascular
smooth muscle cells where activation by ET-1 mediates dilation and constriction,
respectively. The role of ET-1 has been implicated in several pathologic states including
endotoxemia, sepsis, myocardial infarction, strangulation obstruction, ulcerative disease,
ischemia-reperfusion and asthma. However, there have been no reports to date
demonstrating a role of ET-1 in gastrointestinal tract disease of horses.
Intestinal strangulation is a common cause of colic that accounts for approximately
10% of all the cases in horses with colic, and is universally fatal without surgical
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intervention and intense medical therapy. Following surgical correction of experimental
large colon volvulus in horses, the intestinal blood flow remains significantly decreased
below baseline values for at least 4 hrs. This sustained reduction in blood flow is likely
associated with disruption in the balance between endothelium-derived vasorelaxants
(NO, PGI2) and vasoconstrictors (ET, PGF2α), resulting in ischemia, progressive mucosal
damage and alterations in gastrointestinal motility. Although there are a plethora of
mediators involved in the pathogenesis of ischemia-reperfusion injury, we propose that
ET-1 is involved in the vasomotor abnormalities and subsequent ischemia. Increased
plasma ET-1 concentrations have been found in various pathological conditions in other
species such as low-flow states, sepsis and shock. We hypothesize that ET-1 is directly or
indirectly involved in the cascade of events involving ischemia, ischemia-reperfusion
injury (I-R) and motility disturbances in the gastrointestinal tract of horses.
The aim of the first study was to validate a commercially available
radioimmunoassay (RIA) for measuring plasma ET-1 like immunoreactivity in horses,
and to quantify and compare the circulating plasma ET-1 concentrations between healthy
horses and in horses with naturally acquired gastrointestinal tract disorders. Additionally,
we investigated the relationship between circulating plasma ET-1 concentrations and
clinical, and clinicopathologic variables and the survival of the affected horses. We
hypothesized that concentrations of plasma ET-like immunoreactivity would be greater in
horses with naturally acquired gastrointestinal disorders, compared with healthy horses,
and the survival of the horses would be inversely correlated with the increased plasma
ET-like immunoreactivity.

3

The aim of the second study was to validate ET-1 immunohistochemical staining in
the gastrointestinal tract of horses, and to evaluate the presence and regional distribution
of ET-1 like immunoreactivity in various segments of the gastrointestinal tract of healthy
horses. Further, we evaluated alterations in the intensity of ET-1 staining in intestinal
segments collected from horses with naturally acquired intestinal strangulation. We
hypothesized that there would be an increase in intensity of ET-1 like immunoreactivity
in the affected intestinal segment of horses with naturally acquired intestinal
strangulation obstruction and this would correlate with the degree of intestinal damage.
The aim of the third experiment was to develop and validate a procedure for
identifying the presence of ET-1 gene expression by polymerase chain reaction in
intestinal sections collected from clinically healthy horses. We hypothesized that the ET1 would be found in variable quantities from various segments of the intestinal tract
extending from the duodenum to the right dorsal colon of healthy horses. We also
hypothesized that ET-1 gene expression would be greater in the mucosa of the jejunum
and pelvic flexure of horses with naturally acquired small intestinal and large colon
strangulation obstruction, respectively.
The aim of the fourth study was to identify and characterize the ET-1 induced in
vitro responses of cecal longitudinal smooth muscle from clinically healthy horses devoid
of any apparent gastrointestinal tract disorders. The roles of ET receptors, ETA and ETB
in ET-1 induced changes in the gastrointestinal tract smooth muscle contractility were
evaluated using specific ETA and ETB receptor antagonists, BQ-123 and IRL-1038,
respectively. Additionally, we clarified the role of ET-1 in nerve-mediated contractions
induced by electric field stimulation. We hypothesized that ET-1 would be a potent
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contractile agent in gastrointestinal tract smooth muscle. Additionally, we hypothesized
that spontaneously contracting and EFS-stimulated ET-1 induced contractile and relaxing
responses would be mediated by ETA and ETB receptors, respectively.
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CHAPTER 2
REVIEW OF LITERATURE

6

2.1 Anatomy of Equine Cecum and Colonic Viscera
Knowledge of the anatomy of equine large intestine, including its gross anatomy,
physiological function and basis of intestinal motility are necessary to understand the
pathophysiologic mechanisms involved in various disease processes.
2.1.1 Cecum
The cecum is a large, comma shaped structure lying along the right dorsal to right
ventral abdomen with its apex near the xyphoid process of the sternum. It is divided into
three regions, namely the apex, body and base with blind ends at both extremities. The
cecum has four teniae that form four rows of sacculations. The cecocolic orifice is
located at the ventral part of the caudal cecal base. The vascular supply to the cecum is
provided by the cecal arteries (lateral and medial), which arise from the ileocolic artery
(Pfeiffer and MacPherson, 1990).
The cecum is an important site of water and electrolyte absorption as well as
microbial digestion of soluble and insoluble carbohydrates. The function of the cecum is
to mix the ingesta constantly and retain it for a sufficient time to complete microbial
digestion. There are four motility patterns recognized in the cecum (Ross et al., 1986).
The first three are the haustral contraction patterns occurring every 20-30 sec that mix the
contents of the cecum from the cranial base to the cranial apex. The fourth contraction is
a progressive contraction pattern, which occurs once at approximately 4-minute intervals
and originates every 4 minutes and originating from the pacemaker site in the cecal body
or apex (Ross et al., 1986). Functional studies of the cecum have shown selective
emptying of gas versus ingesta following contractions, and the prevention of reflux into
the cecum from the colon due to an anatomic barrier, the cecocolic junction (Argenzio et
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al., 1974). Histologically, the cecum consists of a thin layer of muscularis externa, with
flattened bands of smooth muscle and a high percentage of elastic fibers. The mucosa
contains short, straight cecal glands with many goblet cells and cuboidal epithelial cells.
The surface epithelium consists of tall columnar cells.
2.1.2 Large Colon
The large colon or ascending colon is shaped as a double horseshoe looping
from the right to left ventrally and then to the left and back to the right dorsally (Pfeiffer
and MacPherson, 1990). It holds an average of 80 L and is approximately 4 m long. The
diameter of the large colon varies considerably depending on the region, with the right
dorsal colon being the largest. Branches of the ileocolic artery, colic branch artery and
right colic arteries supply right and left ventral colon and right and left dorsal colon,
respectively (Pfeiffer and McPherson, 1990). The pelvic flexure is a horse-shoe shaped
segment of the large colon between the left ventral colon orally and to the left dorsal
colon aborally. The pelvic flexure is situated in the left one-half of the abdomen and is in
contact with the abdominal wall close to the pelvic inlet (Pfeiffer and MacPherson,
1990). The pelvic flexure cannot be unfolded as its mesentery is attached to the
mesocolon, which holds the ventral and dorsal colon parallel. The pelvic flexure is
devoid of sacculations and is smaller in diameter (5.25 cm) compared with the left dorsal
and ventral colons (9.25 cm) (Burns and Cummings, 1991). The abrupt narrowing of the
pelvic flexure predisposes to impaction. The right colic artery and colic branch artery
anastomose at the pelvic flexure. Blood vessels enter the submucosa through the tunical
muscularis and form the submucosal arteriolar plexus. Arterioles ascend from the
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submucosal plexus to mucosa and form an extensive capillary network around the
colonic glands.
The colon has a thin mucosal layer, with colonic glands separated by extensive
lamina propria. The cells lining the colonic glands are goblets cells and granular cells
(Pfeiffer and McPherson, 1990). The outer muscularis externa is thick and has bands of
smooth muscle and elastic fibers (Pfeiffer and McPherson, 1990). A thin-layered
muscularis mucosa is present, and villi are absent. Few lymphoid follicles are also seen
in the colon.
The main function of large intestine or ascending large colon is microbial
fermentation of carbohydrates. Up to 75% of the energy requirement is met by the
production of volatile fatty acids through the microbial digestion process. Further, a large
quantity of fluid is secreted and resorbed (upto 95%) in the large colon (Argenzio et al.,
1974).
2.2 Physiology of Gut Motility
The control of gut motility is complex but well coordinated. Gastrointestinal
motility is controlled and regulated by the enteric nervous system and modulated by a
delicate interaction between myogenic, neural and humoral mediators. Gastrointestinal
motility is affected by the ability of gastrointestinal smooth muscle to generate cyclic
changes in the resting membrane potential. A basic pattern of electromyographic activity
in the intestine characterized by a low frequency, low amplitude wave or basic electric
rhythm (BER), with superimposing action potentials (spikes of high frequency and
amplitude) has been established (Davies and Gerring, 1985).
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The membrane potential of smooth muscle depends on the selective ion
permeability of ions and NaK-ATPases within the membrane. The resting membrane
potential (-60mV) triggers smooth muscle contraction through the influx of calcium ions
(Casteels, Droogmans, Reaymaekers, 1989). Calcium ion channels are sensitive to
change in the membrane potential. If the membrane potential exceeds threshold, these
channels are active and result in a rapid increase in calcium concentration in the
sarcolemma and initiate smooth muscle contraction. In the gastrointestinal tract, the
resting membrane potential varies between –35 and –75mV, causing the BER. The ion
movements across the smooth muscle membranes generate the BER. Although the BER
originates in the smooth muscle, it can be mediated by neural and humoral factors
(Davies, 1989).
Two recognized patterns of contractility are segmentation and peristalsis.
Segmentation creates the slow aboral transit of ingesta and mixing ingesta with
gastrointestinal secretions, whereas peristalsis promotes transit in an aboral direction
(Davies, 1989). Peristalsis is accomplished by a combination of circular and longitudinal
muscle contractions. During peristaltic movements, the longitudinal muscle acts first for
long stretches and subsequently circular smooth muscle contract/relax initiating
propulsive movements of the intestine. Other factors such as digesta viscosity, pressure
gradients and gravitational forces are important in influencing gastrointestinal motility in
horses (Weems, 1982). During the preparatory phase of peristaltic movement, circular
smooth muscle relaxes and longitudinal muscle contracts and when filling pressure
increases both circular and longitudinal smooth muscle contracts. Thus, shortening and
constricting movements of the equine cecum occur by the synchronized contractions of
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circular and longitudinal smooth muscle, occurring approximately every 4 minutes
(Sellers and Lowe, 1986).
The small intestinal contractions have an organized cyclical pattern, termed the
migrating myoelectric complex (MMC). The motility pattern of the large intestine is
more varied because the BER is present intermittently and at a variable frequency. Based
on the duration of spike activity, two major patterns of electrical activity have been
observed in the equine large colon. Short spike bursts (lasting < 5 sec) and long spike
bursts (10-20 sec) are involved in mixing contractions, and in cecocolic retropulsion and
colic propulsion, respectively (Ross, Rutkowski, Cullen, 1989). Extrinsic innervations of
the large colon include parasympathetic fibers from vagal nerves and sympathetic fibers
from the cranial mesenteric ganglia. Generally, parasympathetic stimulation tends to
increase contractile activity of the gastrointestinal tract and sympathetic stimulation
causes the opposite effect. In addition to its extrinsic innervation, the enteric nervous
system plays an important role in the maintenance of gut motility. The enteric nervous
system has two main plexi, namely the myenteric (Auerbach’s) plexus and the
submucosal (Meissner’s plexus). The myenteric plexus is located between the circular
and longitudinal smooth muscle layers and the submucosal plexus is positioned within
the submucosa. The myenteric and the submucosal plexuses contain excitatory
cholinergic neurons, excitatory and inhibitory adrenergic neurons, and excitatory and
inhibitory non-adrenergic, and non-cholinergic (NANC) neurons (Boeckxstaens et al.,
1993).
Gastrointestinal hormones or gut peptides such as gastrin, cholesytokinin,
secretin, glucagon, motilin and pancreatic polypeptide tend to influence intestinal
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motility, secretion, and blood supply. Prostaglandins (E and F) alter smooth muscle tone,
and are found to be associated with visceral pain during mild colic (Roger and
Ruckebusch, 1987). Compared with other intestinal segments, a greater number of
ganglia and neurons per cm were found in the wall of the pelvic flexure suggesting the
presence of a ‘pacemaker’ in the region (Schusser and White, 1997). Neurotransmitters
such as substance-P, methionine-enkephalin, calcitonin gene-related peptide and
vasoactive intestinal peptide (VIP) were found in the wall of the pelvic flexure (Burns
and Cummings, 1993). Studies have shown that injury to the myenteric plexus during
strangulation obstruction may permanently reduce the neuronal density, leading to
compromise of function and possibly development of an impaction (Schusser,
Scheidemann, Huskamp, 2000). This finding is in agreement with a higher incidence of
colic in horses with history of large colon impaction (Dabareiner and White, 1995).
Sellers & Lowe (1986) proposed that malfunction of the pelvic flexure pacemaker is one
of the reasons for large colon displacement and torsion.
2.2.1 Motility Disturbances
In horses, various gastrointestinal tract disorders such as ischemia,ischemiareperfusion (I-R) injury, impaction, endotoxemia, and parasitism result in disturbances of
gastrointestinal motility. Various endogenous mediators, electrolyte imbalances and
neural factors are involved in the pathogenesis of intestinal dysmotility associated with
abdominal disorders. Postoperative ileus results from disruption in the balance between
the excitatory and inhibitory neurotransmitters secondary to inflammation, endotoxemia
and intestinal distention (Bilkslager et al., 1994). Disruption in cecal motility and
emptying may be a key factor in the etiopathogensis of cecal impaction (Collatos and
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Romano, 1993). However, the mechanism has not been fully elucidated mainly due to an
insufficient understanding of neurohumoral control of gastrointestinal motility.
Experimentally-induced pelvic flexure impactions in ponies caused mild persistent
colic characterized by increased large colon contractile activity (Lowe, Sellers, Brondum,
1980). In experimentally-induced extraluminal obstruction in ponies, the motility of
intestine proximal to the obstruction was increased. In horses, endotoxemia has been
shown to cause cecal and proximal colonic ileus and cecal hypoperfusion through a
mechanism involving alpha-2 adrenergic receptors (Eades and Moore, 1993).
Ischemia-reperfusion injury leads to profound functional and structural alterations
in the activity of the gastrointestinal tract. In rats, I-R injury is characterized by functional
dysmotility of the duodenum and jejunum with prolonged duration of contraction and a
decreased number of contractions, respectively (Takahashi et al., 2001). In addition, the
interdigestive MMC cycling time was found to increase during the ischemic period in
experimentally induced I-R model in piglets, with no change during reperfusion (Hebra et
al., 1993). The impaired motility during I-R is attributed to the release of superoxide and
other vasoactive mediators such as ET and NO.
2.3 Regulation of Intestinal Blood flow
2.3.1 Role of Endothelium
Endothelium is a metabolically active layer, consisting of a single layer of flattened
and polygonal cells lining the circulatory system (Bennet, Luft, Hampton, 1959). These
cells are coated with a carbohydrate-rich cell coat, glycocalyx, consisting of
glycosaminoglycans and polysaccharide chains of the plasma membrane glycoproteins
and glycolipids (Borsum, 1991). Vascular endothelium is increasingly recognized as the
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central mediator of a number of important processes in vascular biology and disease.
Until recent years, it was considered simply as a barrier between blood and extravascular
tissue. However, endothelial cells play a pivotal role in the balance between coagulation
and fibrinolysis, immune responses, regulation of blood pressure and perfusion, and
mediate local inflammatory responses (Pearson, 1991).
Recent studies have demonstrated that endothelium plays a critical role in
regulation of vascular tone by releasing various vasoactive mediators such as endothelialderived vasorelaxant (NO, prostacyclin) and vasoconstrictor (ET, prostaglandins) agents,
which are major determinants in maintaining blood flow. Endothelial damage can disrupt
the balance between vasorelaxant and vasoconstrictor substances, which lead to increased
vasosmotor tone, resulting in increased intestinal vascular resistance and subsequent
reduction of blood flow. The most likely endothelium-derived vasoactive mediators
involved are NO and PGI2 (vasorelaxants) and ET-1 (vasoconstrictor).
2.3.2 Endothelin and Nitric Oxide
Various endothelial-derived contracting and relaxing factors are released following
humoral, mechanical and neural stimulation of the endothelium, and the balance between
these factors is responsible for the control of vascular tone and blood flow (Brenner,
Troy, Ballerman, 1989). Endothelial cells synthesize NO (vasodilator, inhibits platelet
aggregation and neutrophil adhesion) and ET-1 (vasoconstrictor and platelet aggregator).
The opposing effects of NO and ET on vascular smooth muscle suggests a regulatory role
of endothelium regarding blood flow and vasomotor tone. Inactivation of NO synthase
and prostaglandin synthesis by N-ω-nitro-L-arginine methyl ester (L-NAME) and
indomethacin, respectively, augmented ET-1 induced contractility in rabbit coronary
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smooth muscle, which impaired coronary blood flow (Berti et al., 1993). The impaired
blood flow during intestinal obstructive disorders in various species may be due to an
imbalance of these mediators (increased ET-1 and decreased NO).
Because of its high metabolic activity and subsequent requirement for blood flow,
the gastrointestinal tract mucosa is a primary target tissue of low-flow conditions such as
hemorrhagic or endotoxin shock (Patel, Kaleya, Sammartano, 1992). One of the principal
homeostatic mechanisms for the host’s response to reduced circulating blood volume
(hypovolemic or endotoxin shock) is to shunt blood away from the gastrointestinal tract
in an attempt to increase the effective blood volume and maintain perfusion of vital
organs (Patel, Kaleya, Sammartano, 1992). The maintenance of blood flow and cardiac
output is achieved mainly through intense sympathetic stimulation, and by other humoral
and vasoactive mediators. The release of sympathetic mediators (epinephrine, norepinephrine) during these conditions causes strong vasoconstriction of arterioles, and
large capacity intestinal and mesenteric veins, thereby displacing the blood volume from
other parts of the circulation (splanchnic) and increasing total peripheral resistance and
venous return. The gastrointestinal tract tissues have high resting O2 uptake (20-25
mL/kg/min) that is normally met by a high blood flow rate (300-500 mL/kg/min)
(Guyton, 2000). If blood flow falls below critical values and the O2 uptake is
compromised, intestinal damage ensues. Thus, gut circulation appears to be more
susceptible to the vasoconstrictor properties of ET-1 than many other peripheral vascular
beds.
The role of splanchnic ischemia or hypoxia in the pathogenesis of shock has
stimulated much interest in the mechanism of intestinal ischemia. Haglund & Lundgren

15

(1987) suggested the presence and induction of unknown vasoactive substances that
reduced the intestinal perfusion or caused systemic shock during low-flow conditions in
the intestine and even after surgical correction of intestinal strangulation obstruction. This
reduction in blood flow is probably due in part to splanchnic vasoconstriction, where
humoral mediation is likely critical and is achieved through the release of endothelialderived mediators. The sensitivity of the intestinal vasculature to ET-1 may be of
considerable importance considering the fact that ET-1 levels are increased in a variety of
instances such as chronic hypoxia, ischemia and sepsis (Cernacek and Stewart, 1989;
Weitzberg et al., 1991; Murch et al., 1992; Fevang et al., 1998).
Non-selective agents should be avoided during pharmacological intervention of
splanchnic circulation. Various experimental data suggest that therapeutic approaches
using selective ET blockers and/or NO donors are beneficial in the treatment of I-R injury
(Oktar et al., 2002; Kalia et al., 2001). The prevention of splanchnic vasoconstriction
using vasodilators has been used in human gastrointestinal surgery (Gentilini et al.,
1999). Selective agents, such as prostaglandin E and glucagons are used to increase
mucosal blood flow. Studies have shown that captopril, an angiotensin antagonist, can
also be used to disrupt angiotensin (vasoconstrictor) secretion during I-R (Guo et al.,
1998). Anticoagulants have been advocated for use in gastrointestinal surgery to prevent
intravascular thrombosis and or/emboli. Heparin administration was found to improve
colonic blood flow, vascular resistance and systemic arterial blood pressures in
experimentally-induced colonic transmural and vascular obstruction for 1 hour in ponies
(Provost et al., 1991). The mechanism of action of heparin lies in its ability to act as a cofactor together with antithrombin III (AT-III), causing increased AT-III as an inhibitor of
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activated clotting factors. However, few studies have shown the beneficial effects of
using these agents to improve equine intestinal blood flow after ischemia.
2.4 Endothelin
The role of endothelium in the regulation of vasomotor tone was elucidated by the
discovery of vasorelaxants synthesized from endothelial cells (prostacyclin, NO)
(Moncada et al., 1976; Furchgott and Zawadzki, 1980). Studies have shown that
endothelium also releases a vasoconstricting peptide, termed endothelial-derived
constricting factor (EDCF) (Hickey et al., 1985). This peptidergic substance was later
purified from supernatant of porcine aortic endothelial cell culture medium, and was
termed endothelin (Yanagisawa et al., 1988). Cloning and sequence analysis has since
revealed three distinct endothelin-related genomic loci in human, pig and rat that encodes
for three similar but distinct peptides, ET-1 (formerly called porcine or human
endothelin), ET-2 and ET-3 (formerly called rat-ET) (Yanagisawa et al., 1988; Itoh et al.,
1988; Inoue et al., 1989). In addition, sarafotoxin (STX) has also been included in the ET
family due to its remarkable similarities in homology and bioactive properties. The
presence of ET in invertebrates and fish indicates its long evolutionary history (Kasuya et
al., 1989).
Endothelins are a family of 21-amino acid peptides (MW 2492) and are the most
potent vasoconstrictors known to date. Endothelins are multifunctional peptides that have
vasoactive, ionotropic, and mitogenic properties (Rubanyi and Polokoff, 1994), and have
the ability to modulate other hormone systems as well as intestinal, renal and pulmonary
function. Expression of ET in non-vascular cells/tissues suggests its diverse role in
physiological and pathological processes (Levin, 1995; Rubanyi and Polokoff, 1994).
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These diverse and complex functions include neurotransmission, stimulation of intestinal
contraction (motility), synthesis of atrial natriuretic factor (ANF), counter-balancing NO
release, inhibition of renin release and control of sympathetic tone (Levin, 1995).
2.4.1 Biology of ET
The human ET-1 gene sequence found in chromosome 6 is 6.8kb in size and
encompasses 6 exons and 5 introns. Each portion of the exon encodes a portion of ET-1,
and exon 2 encodes the majority of prepro-ET-1 (Lee et al., 1990). The promotor region
has the typical CAAT and TATA sequences regulating transcription and has several
responsive elements, which provide regulatory sites for various stimuli (Lee et al., 1990).
The genes for ET-2 and ET-3 are located on chromosome 1 and 20, respectively. The
equine ET-1 has not been completely sequenced, however, a group of scientists have
cloned and published the partial sequence of chromosomal ET-1 gene (Gene Accession #
AF130760).
2.4.2 Endothelin Isoforms
Each of the isoforms of ET is a product of separate genes that encode the large
precursor, prepro-ET. Endothelin-1, is the predominant type of ET, but ET-2 and ET-3
also exist. Vasointestinal constrictor (VIC), also known as β-endothelin, has been
demonstrated in murine intestine (Inoue et al., 1989) and differs from ET-1 by three
amino acids (in positions 4, 6 and 7).
Endothelin-1 is the most abundant circulating ET isoform, and has been best
characterized (Rubanyi and Polokoff, 1994). Of all the endothelin types, the principal ET
of importance in vascular diseases is ET-1, and is the only isoform synthesized by the
endothelium. Endothelin-1 is also found in smooth muscle, airway epithelium and other
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cell types. The ET-1 and ET-3 isoforms have been found in nearly every organ examined
including different segments of the gastrointestinal tract of rats (Matsumoto et al., 1989;
Firth and Ratcliffe, 1992). The ET-3 isoform also circulates in the plasma and is found in
the central nervous system, kidney and lung, however, the cellular source is not clear
(Hemsen and Lundberg, 1991). The presence of ET-3 in the brain suggests its role in
important functions including astrocyte proliferation and development (Shinmi et al.,
1989). However, the expression of ET-2 is much more limited and found predominantly
in the kidney and intestine, where its function remains unclear (Levin, 1995).
2.4.3 Biosynthesis of ET
Endothelin levels are controlled at the level of transcription of its precursor,
preproendothelin (preproET). Endothelin isoforms are processed from prepro-ET to form
pro-ET, which is then post-translationally converted into the active peptide, ET.
Endothelins are derived from unusual proteolytic cleavage of large pre-proET
(approximately 203 amino acid) by specific dibasic endopeptidases. Each pre-proET has
a distinct gene and amino acid sequence processed to the polypeptide prohormone, big
ET, of various lengths (37-41 amino acids). The polypeptides (big ETs) are cleaved in the
cytoplasm by the proteolytic action of membrane-bound metalloproteinases, endothelinconverting enzymes (ECE), into ET and a C- terminal fragment-1 (CTF-1) (Figure 2.1).
The big ET-1 has very low biologic activity. The enzymatic process of the synthesis of
mature ET-1 occurs by unusual proteolytic cleavage of big ET-1 between Trp21 and Val22
by ECE (in case of big ET-3 it is between Trp21 and Ile22) (Opgenorth, Wu-Wong,
Shiosaki, 1992). The conversion of big ET-1 to ET-1 by ECE is essential for the
expression of full vascular activity. A group of five distinct ECE isoforms, ECE-1a, ECE-
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Figure 2.1 Biosynthesis of endothelin-1. Abbreviations: S-S – disulfide bond; CRconserved region; VR- variable region.
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1b, ECE-1c, ECE-2 and ECE-3 have been cloned and classified (Turner and Murphy,
1996; Schweizer et al., 1997), each with a different tissue distribution and pH
requirement for activity. Each bioactive form of the ET isoforms is synthesized by
specific conversion between Trp21-Val22 and Trp21-Ile22. The ECE isoforms are found in
many cell types including endothelium, epithelium and alveolar macrophages (Takahashi
et al., 1993; Ohnaka et al., 1990). However, ECEs have not yet been identified that are
selective for ET-2 and ET-3. Greater than 80% of the ET-1 synthesized by the
endothelium is secreted abluminally toward the tunica media away from the luminal
surface of the airway or vessel (Wagner et al., 1992). Directional secretion allows ET-1
to act in a paracrine or autocrine manner whereas secretion into the circulation allows
ET-1 to act as a hormone.
The half-life of ET mRNA is 20-30 minutes, whereas the ET peptide has an
extremely short half-life of 4-7 minutes. Endothelins are stable in plasma, predominantly
cleared or metabolized in the lung during their first passage (90%), and excreted in small
amounts via the kidney and liver (de Nucci et al., 1988). In rats and humans, the lung is
responsible for ET-1 elimination; however, in pigs the renal and splanchnic circulation
are involved in ET-1 clearance. Some studies suggest that ET is eliminated from blood
quickly and is likely followed by the internalization of the peptide into the tissue
parenchyma and/or vasculature of various tissues (Anggard et al., 1989; Shiba et al.,
1989). The pathway of ET synthesis is well defined, but its complex process of
degradation, which also determines its biologic activity, is not completely understood.
2.4.4 Endothelin Structure
Endothelin is a family of 21 amino acid peptides with free amino and carboxy-
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terminal, which include four cysteine residues at positions 1, 3, 11 and 15, forming two
intra-molecular disulfide linkages between Cys1 and Cys15, and Cys3 and Cys11
(Yanagisawa et al., 1988). The presence of the disulfide bonds provides a compact NH2
terminal core region consisting of outer and inner loops. The disulfide bonds present in
ET are vital to its high affinity binding to one class of ET receptors, but are of less
importance in recognition by the other class of ET receptors. Amino acid residues 4-7
comprise the variable region, residues 12-14 are highly unpolar regions, and residues 1621 are hydrophobic. The hydrophobic C terminus in all three ET isoforms is strictly
conserved. The terminal tryptophan region of ET has been shown to be essential for its
full biologic activity. The ET-2 isoform exhibits the closest structural similarity to ET-1,
differing by only two amino acid residues at positions 6 and 7, whereas ET-3 differs from
ET-1 by six amino acids at positions 2, 4, 5, 6, 7 and 14 (Figure 2.2). These peptides
exhibit different degrees of vasoactivity and it has been suggested that the overall charge
of the inner Cys-Cys loop may be an important determinant of this property (Kloog and
Sokolovsky, 1989).
2.4.5 Endothelin Receptors
The use of radiolabelled ET in autoradiographic and standard ligand binding studies
has demonstrated that the ET isopeptide binding sites are distributed in a wide variety of
both adult and fetal organs and tissues in different species (Davenport et al., 1989;
Takayanagi et al., 1991). The binding sites have been shown in locations such as the
central nervous system, lung, gastrointestinal tract (stomach, small intestine and colon)
and within the cardiovascular system (Power et al., 1989; MacCumber, Ross, Snyder,
1990). Two independent groups have reported the cloning, sequencing and functional
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expression of endothelin receptors (Arai et al., 1990; Lin et al., 1991). Two types of ET
receptors were cloned, termed endothelin A (ETA) and endothelin B (ETB) with size
ranging between 45,000-50,000 daltons. The ETA and ETB receptor
genes are located on human chromosomes 4 and 13, respectively (Arai et al., 1990;
Sakurai et et al., 1990). There is a high degree of sequence identity at the amino acid
level (90%) between the receptor subtypes, however, little homology is found between
the two receptor types, ETA and ETB. The greatest diversity occurs in the extra-cellular
domain and in the cytoplasmic COOH region. Both ET receptors (ETA and ETB) belong
to a family of heptahelical G-protein-coupled receptors. The ET receptors have an
extracellular NH2 terminal region, transmembrane helices separated by 3 extracellular and
3 cytoplasmic loops with a terminal cytoplasmic COOH region. Endothelin is hydrophilic
and thus unable to cross plasma membranes. The saturable binding sites are present in the
cell wall, and it is presumed that ET acts by binding to these receptors.
All three ET isoforms bind to their distinct receptors in mammalian cells that have
different affinities to endogenous ligands. The two main types of ET receptors found in
smooth muscle and endothelium are ETA and ETB, respectively. These receptor types
originally identified in the vasculature have also been found in many other organs such as
the liver, brain, kidney and gastrointestinal tract, with the greatest concentrations in heart
and lung; this suggests ET’s pleiotropic function. The ETA receptor is principally found
in vascular and airway smooth muscle cells and has 10 times more binding affinity for
ET-1 than for ET-3 (Rubanyi and Polokoff, 1994). The affinities for binding of the ET
isoforms to ETA receptors are in the order: ET-1 > ET-2 > ET-3 (Rubanyi and Polokoff,
1994). Currently two subtypes of ETB have been cloned and characterized, namely ETB1
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Figure 2.2 Endothelin isoforms. The dark colored circle represents variable amino acid
region compared to ET-1.
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and ETB2. The ETB1 receptors are found in the endothelium and mediate the release of
NO and prostacyclin causing vasodilatation (de Nucci et al., 1988; Sakurai et al., 1990),
whereas ETB2 receptors on the smooth muscle mediate vasoconstriction. Thus, binding of
ET-1 with ETA receptors leads to constriction and with ETB1 causes dilatation. The
difference in tissue-specific expression between ET receptor types and subtypes
contributes to the different actions of endothelin. Within a particular tissue, the
distribution of ETA and ETB receptors varies. Consistent with functional activity of ET-1
in intestinal smooth muscle, ET-1 binding sites have been documented in the stomach,
ileum, jejunum, and colon of rats (Koseki et al., 1989; Takahashi et al., 1990) and guinea
pig (Bolger et al., 1992). In the kidney, the ETA receptors are found predominantly in the
vasa recta whereas ETB is found mostly in the collecting ducts (Simonson, 1993). In
horses, a genetic polymorphism of the ETB receptor is linked to the Overo Lethal White
Foal Syndrome in paint foals, characterized by spastic colon and intestinal
aganglioneurosis (Yang et al., 1998).
2.4.6 Endothelin Signal Transduction Mechanism
Endothelins bind to receptors and elicit their effects, such as vasoconstriction and
vasodilatation, via signal transduction pathways through G-protein activation (Figure
2.3). The G-proteins have various subunits such as Gs, Gi and Gq. The Gs alpha subunit
primarily activates adenylyl cyclase that catalyzes the formation of cAMP from ATP.
The Gi alpha subunit inhibits adenylylate cyclase. The Gq alpha subunit activates
phospholipase C (PLC) that cleaves phosphotidylinositol-4, 5-bisphosphate (PIP2) in the
cell membrane to release diacylglycerol (DAG) and inositol-(1, 4, 5)-triphosphate (IP3).
The principal protein affected by the activation of phospholipases is protein kinase-C
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(PKC), which is maximally active in the presence of calcium ion and DAG. The PLC
contains SH2 domains that allow it to interact with tyrosine phosphorylated receptor
kinases. This allows PLC to be intimately associated with the signal transduction
complexes of the membrane as well as membrane phospholipids that are its substrates.
The phosphoinositide cascade is mediated by membrane bound enzyme PLC,
which is activated by ET binding to its receptors (Simonson et al., 1989). The IP3 causes
the release of Ca2+ stores in the endoplasmic reticulum and sarcoplasmic reticulum,
increasing the levels of Ca2+ in the cytosol. The increased level of cytosolic Ca2+ then
causes smooth muscle or vascular contraction. The DAG and Ca2+ activate PKC,
catalyzing phosphorylation of serine-threonine residues of various target proteins
mediating mitogenic action.
Endothelin-induced contraction is mediated by the activation of nonselective
cation channels permeable to calcium (Zhang et al., 2000). The binding of ET to its
receptor leads to the activation of Gsα subunit of adenylyl cyclase, forming cAMP from
ATP. The cAMP acts as an intracellular messenger and catalyzes various other cellular
functions. The ET-induced vasoconstriction is a biphasic response, whereby a period of
transient vasoconstriction is followed by a distinct and sustained vasoconstriction. The
transient vasoconstriction observed with ET release is attributed to the release of Ca2+
from the intracellular calcium stores and the characteristic sustained vasoconstriction is
mediated mainly through the persistent entry of extracellular calcium through calcium
channels of the plasma membrane (Masaki, 2000). The vasodilator action of the ETactivated receptor, ETB1, is attributed to the release of NO and prostacyclin or increased
levels of cGMP through activation of Gi. The Gi activation has been shown to cause
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inhibition of adenylate cyclase and activation of the Na+-H+ antiporter (Aramori and
Nakanishi, 1992; Koh et al., 1990). Another function of the ET receptor is to mediate the
growth activity of cells such as smooth muscle or endothelial cells (mitogenic). This
activity is mediated through various mechanisms, i.e., classical PKC-dependent and independent pathways.
2.4.7 Endothelin Receptor Antagonists
A number of ET receptor antagonists have been developed and tested in animal
models. The first ET antagonist developed for human testing was a natural by-product of
Streptomyces misakiensis. However, this ET antagonist has low binding and functional
properties. A series of peptide antagonists for endothelins selective toward ETA (BQ
123), ETB (BQ 788, IRL-1038 ) and both ET-A/ET-B receptors (PD 142893, TAK-044,
RO 46-2005) have been designed. A competitive ET antagonist, BE-18257, a cyclic
pentapeptide was shown to have very low potency in binding and functional assays
(Benigni and Remuzzi, 1999). These compounds are hydrolyzed by circulating
peptidases, and do not penetrate the blood brain barrier when given orally (Benigni and
Remuzzi, 1999). Recently, synthetic non-peptide antagonists have been developed (PD
155080-Bosentan, BMS 182874, SB 209676) and they prodced mixed results (Benigni
and Remuzzi, 1999).
2.4.8 Factors Involved in ET-1 Expression and Secretion
Endothelin-1 levels are controlled at the level of transcription of its precursor,
preproendothelin-1. The upstream regulatory element of the ET gene contains an acute
phase response element, which is activated by various important stimuli (Inoue et al.,
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Figure 2.3 Mode of action involved in ET-1 induced constriction, relaxation and
mitogenesis. VOC-voltage operated channel, PKC-protein kinase C; DAGdiacylglycerol; IP3- inositol triphosphate; NO- nitric oxide; PLC- phospholipase
C PIP2- phosphatidylinositol biphosphate; MLC-myosin light chain; MLC-Pphosphorylated myosin light chain; PGE2-prostaglandin E2; PGI2-prostoglandin
I2 and RER-rough endoplasmic reticulum.
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1989). The ET-1 synthesis is controlled by a number of physical and humoral factors
(Kurihara et al., 1989; Emori et al., 1989; Kourembanas et al., 1991; Kanse et al., 1991;
Malek and Izumo, 1992). The physical factors include shear stress and hypoxia. The
humoral factors involved in ET-1 synthesis are hormones (vasopressin, angiotensin,
epinephrine, insulin), bradykinin, cytokines (tumor necrosis factor-(TNF)-α, interleukin(IL)-1), growth factors such as transforming growth factor (TGF)-β, platelet activating
factor (PAF) and endotoxin. The suppressors include NO, atrial natriuretic factor (ANF)
and cGMP.
2.4.8.1 Physical Factors
Low shear stress causes increased ET-1 mRNA expression and ET release in
cultured aortic endothelial cells (Yoshizumi et al., 1990). However, bovine aortic
endothelial cells exhibited a dose-dependent decrease in ET-1 mRNA expression with
increased shear stress (Malek and Izumo, 1992). Also, Kourembanas et al. (1991)
demonstrated increased ET-1 mRNA expression in cultured human umbilical vein
endothelial cells to low oxygen tension.
2.4.8.2 Humoral Factors
Cytokines such as TNF and IL-1 are identified as the primary mediators in the
pathogenesis of sepsis and are important modulators of ET-1 secretion (Kahaleh and Fan,
1997, Kruse-Elliot, Whorton and Olson, 1998). In vitro ET synthesis increases in cultured
porcine aortic endothelial cells stimulated with TNF and IL-1 (Kanse et al., 1991;
Yoshizumi et al., 1990). Also, IL-1 and IL-1β increase ET-1 mRNA levels and ET
synthesis in a dose-dependent manner (Yoshizumi et al., 1990). It is speculated that an
IL-1-endothelin axis exists between macrophages and smooth muscle cells, which
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implicates its role in vasospasm. But additional studies have shown that IL-1β, IL-6 and
IL-8 have no effect on ET-1 synthesis and release from cultured endothelial cell, whereas
interferon-γ and TNF have only a small effect (Kanse et al., 1991).
Cytokines released by activated platelets such as TGF-β induces ET-1 gene
expression by binding to nuclear factor-1 (NF-1) (Kanse et al., 1991), but the role of TGF
in modulation of ET-1 secretion during I-R is unknown. Various hormones like
vasopressin and angiotensin-II induce an increase in endothelial ET-1 mRNA levels
(Emori et al., 1989). The induction and secretion of ET-1 by TGF-β in endothelial cell
cultures is in a manner similar to thrombin (Kurihara et al., 1989). Thus, during vascular
injury and thrombin formation, ET-1 may play a role in local constriction via the release
of TGF-β from activated platelets. Taken cumulatively, these results suggest that the
production of ET-1 in endothelial cells is regulated by factors associated with platelet
aggregation and macrophage infiltration.
Tumor necrosis factor, an important primary mediator of endotoxemia, increases
the transcriptional rate of the ET-1 gene (Marsden and Brenner, 2000). Endotoxin
stimulates monocytes/ macrophages to release TGF, IL-1 and IL-6 (Morris, 1991, Morris
et al., 1992). These mediators initiate and perpetuate a cascade of inflammatory events
that can lead to endotoxic shock and multiple organ failure. Stimulation of cultured
vascular smooth muscle cells with TNF-α (10 ng/mL), IFN-γ (1,000 U/mL), IL-1β (500
U/mL) and lipopolysaccharide (10 micrograms/mL) for 48 hrs markedly increase the ET1 mRNA expression and ET-1 secretion (Woods et al., 1998). This suggests that these
mediators, TNF and IL-1, released during endotoxemia may stimulate and augment
synthesis and release of ET from the vascular endothelium.
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2.5 Colic
Gastrointestinal tract disease is the leading natural cause of death in adult horses,
(Baker and Ellis, 1981) and most horses are afflicted by colic sometime during their
lifetime. Acute gastrointestinal tract diseases of the equine abdomen associated with pain
are termed ‘colic’. The mortality rate for colic was shown to be the highest of any cause
of death in horses, including old age and injury (Tinker et al., 1997). The etiology and
pathophysiology of colic is complex and varied.
Small intestinal strangulating obstruction secondary to twisting around its
mesentery or incarceration and strangulating large colon volvulus are common causes of
colic in horses, and are associated with high mortality (Barclay, Foerner, Phillips, 1980;
Harrison, 1988; MacDonald et al., 1989). The poor prognosis for survival following
surgical correction of intestinal strangulation obstruction in horses despite appreciable
advances in medical care is associated with a sustained reduction in intestinal blood flow
and mucosal perfusion with changes in microvascular permeability leading to edema,
congestion, hemorrhage, and ultimately, necrosis of the mucosal layer (Snyder et al.,
1990; Wilson et al., 1994; Darien et al., 1995).
Most cases of naturally acquired intestinal strangulation obstruction in horses
involve simultaneous arterial and venous occlusion, with venous occlusion being more
predominant. Strangulating obstruction of the large colon and small intestine are the most
common causes of vascular occlusion in horses with colic (Barclay, Foerner, Phillips,
1980; Huskamp, 1982). Vascular occlusion of the intestine may be induced by parasitism,
with subsequent thromboembolism, and or by strangulation obstruction. Intestinal
ischemia (strangulating large colon volvulus and small intestinal strangulation
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obstruction) is universally fatal without surgical intervention. Up to one-half of the deaths
attributed to colic are associated with lesions in the large intestine (Pascoe et al., 1983).
Ischemic injury to the mucosal epithelium occurs predominantly during
strangulation obstruction; however, intestinal injury can progress after surgical correction
owing to either continued ischemia associated with microvascular thrombosis or
splanchnic vasoconstriction during the postoperative period. Intestinal blood flow has
been shown to remain significantly depressed below the baseline values for at least four
hours after correction of experimentally induced complete arteriovenous occlusion of the
large colon in ponies (Wilkins et al., 1994). Thus, even after surgical correction and/or
resection of affected intestine the remaining intestine is predisposed to continued
ischemic damage resulting in increased mortality (Fischer and Meagher, 1986).
Alternatively, damage induced by ischemia likely continues after blood flow is restored,
which is initiated by cytotoxic reactive oxygen metabolites and perpetuated by
neutrophils and other mediators (Moore, Muir, Granger, 1995). This process is known as
ischemia-reperfusion injury. Endotoxemia is estimated to occur in nearly 25% of horses
with colic; most of these cases involve intestinal ischemia or inflammation (King and
Gerring, 1988). The high mortality subsequent to intestinal ischemia is associated with
disruption of the intestinal mucosal barrier, which allows translocation of luminal
endotoxin and bacteria into the systemic circulation, resulting in endotoxemia and
circulatory shock. Thus, eventually horses succumb to the effects of endotoxic and
hypovolemic shock.
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2.5.1 Classification of Colic
Colic can be classified into various types based on the etiology and the intestinal
segment involved. Colic has been anatomically and functionally classified as simple
obstruction, strangulating obstruction, non-strangulating infarction, enteritis, peritonitis,
ulceration and ileus (Tinker et al., 1997). The non-specific colic cases without definitive
diagnosis are referred commonly as medical, spasmodic, flatulent, or mild colic; and may
be attributed to numerous factors including diet or parasites (Parry, 1983).
2.5.1.1 Simple Obstruction - Impaction
Simple obstruction of the intestine involves luminal obstruction without vasucular
compromise, the most common of which is the impaction of the intestinal tract. This type
of simple obstruction is more common in horses, and accounts for nearly 30% of all colic
cases admitted to referral centers (Dabareiner and White, 1995). Impaction results from
accumulation of ingesta in the intestinal tract, which may be due to abnormalities in
myogenic, humoral and neurogenic control of gut motility (Stanghellini, 1988), thereby
disrupting aboral propulsion of ingesta. Obstruction and dehydration of ingesta in the
gastrointestinal tract also lead to impaction.
Impaction often develops at sites of narrowed luminal diameter such as the pelvic
flexure or just proximal to the transverse colon in the right dorsal colon. The common
sites for impaction in the horse include the ileum, cecum, pelvic flexure, right dorsal
colon and small colon (White and Dabareiner, 1997). Partial obstruction is more common
in the cecum, large colon and small colon, where gas and fluid often pass around the
ingesta. Cecal impaction is the most common cause of cecal disease and obstruction,
accounting for up to 5% of colic cases admitted to US veterinary teaching hospitals.
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Cecal impaction is more common in the cranioventral part of the cecal base (White,
1980). Local distention due to the impacted mass can causes alterations in circulation to
the bowel wall, thereby increasing capillary permeability and loss of fluid and protein
into the peritoneal cavity and bowel. Likewise, focal areas of mural ischemia can occur
due to distention and or pressure from the ingesta mass.
2.5.1.2 Strangulation Obstruction
Occlusion of the intestinal blood flow with simultaneous blockade of the intestinal
lumen is defined as intestinal strangulation obstruction (Schwartz and Stores, 1969).
Strangulation obstruction can be further divided into hemorrhagic and ischemic
strangulation obstruction. Hemorrhagic strangulation obstruction is characterized by
arteriovenous occlusion and luminal obstruction; however, venous occlusion
predominates and with some patent arterial blood flow (White, 1990; Snyder JR, 1989).
This often results in severe mural hemorrhage, edema and eventually necrosis. Clinically,
this is the most common type of strangulation obstruction in the horse. Ischemic
strangulation obstruction is characterized by simultaneous venous and arterial occlusion
together with luminal obstruction. Despite the type, strangulation obstruction leads to
rapid injury to the intestinal mucosa, a highly metabolically active layer. Depending on
the extent of ischemia, strangulation obstruction can also be further classified into warm
and cold type. In the ‘cold’ type there is a complete blood loss (no flow, as in organ
transplantation), whereas in the ‘warm’ type there is reduced flow (Southard, 1990).
Strangulating large colon volvulus is a common and frequent cause of fatal colic
requiring surgical intervention (Barclay Foerner, Phillips, 1980; Harrison, 1988; Snyder
et al., 1989). Approximately 80% of the colon is unanchored and able to move freely in
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the abdomen; because of this anatomical arrangement, it is prone to volvulus, especially
at the base of the colon. Unfortunately, the major blood vessels of the colon, the dorsal
and ventral colonic arteries, enter the mesentery at this location. With the onset of colonic
volvulus, the twisting and stretching of the vessels in the mesentery compresses the
vasculature (Fischer and Meagher, 1986), resulting in colonic mucosal ischemic injury
and epithelial barrier disruption owing to reduced or absent blood flow.
Vascular occlusion is commonly associated with large colon volvulus, which
accounts for 7-40% of horses requiring colic surgery (Barclay, Foerner, Phillips, 1980;
Huskamp, 1982). If the mucosa is not irreversibly damaged during the volvulus, the
epithelium may re-establish an intact mucosal barrier through various mechanisms
(Blikslager et al., 1997). Intestinal strangulation obstruction leads to characteristic lesions
such as gas and fluid distention, edema, congestion, hemorrhage, necrosis and eventually
gangrene or rupture (or both) (Van Hoogmoed et al., 2000). The extent of damage varies
from mild mucosal injury to complete loss of mural wall integrity and subsequent
endotoxemia, hypovolemia and shock. The magnitude of injury depends on the degree
and duration of lack of blood supply and the metabolic status of the animal. Despite
improvement in surgical techniques and post-operative medical care, the survival rate
after correction of large colon volvulus is low (21-42%) (Fisher and Meagher, 1986).
Small intestinal strangulation causes acute, severe colic pain due to intestinal
ischemia. Small intestinal strangulation may occur from small intestinal volvulus,
incarceration through a mesenteric rent or a natural opening such as epiploic foramen or
inguinal ring. The incidence and frequency of small intestinal strangulation obstruction
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varies depending on age and other risk factors (Morris, Moore, Ward, 1989).
2.6 Ischemia-Reperfusion Injury
2.6.1 Ischemia
Ischemia is defined as a critical reduction of blood flow that occurs either due to
functional constriction or mechanical obstruction of blood vessels (thrombus), leading to
inadequate tissue perfusion and oxygenation (Fantone, 1990; Grum, 1990). Reduction in
blood flow causes a reduced oxygen supply to the tissues, resulting in disruption of
normal cellular and bioenergetic pathways (Fantone, 1990; Grum, 1990). Oxygen is
essential for normal cellular function and survival. Oxygen deprivation leads to failure of
oxidative phosphorylation and a decrease in ATP production, which is detrimental to the
metabolic needs of the tissues.
As the oxygen concentration decreases, anaerobic glycolysis occurs in an attempt to
maintain cell function (Grum, 1990). These changes cause a decreased intracellular pH
due to the accumulation of lactic acid and hydrogen ions from ATP hydrolysis. The
accumulated lactic acid further inhibits ATP production and results in increased
intracellular acidosis. Due to the lack of ATP, the Na+-K+-ATPase pump function is
altered resulting in increased intracellular calcium concentration. Thus, increased
intracellular pH, and accumulation of Ca2+ together with the release of proteases, lipases
and other degrading enzymes results in autolytic destruction of cellular organelles and
eventually results in cell death (Moore, Muir, Granger, 1995). Thus, a reduction in blood
supply to the intestinal tract results in rapid injury and death of the highly energydependent mucosal epithelial cells.
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2.6.2 Reperfusion Injury
Reperfusion injury is defined as tissue damage sustained on restoration of blood
flow after a period of ischemia (Moore, Muir, Granger, 1995). Reperfusion injury occurs
as a result of a complex series of cellular metabolic events that are initiated during the
ischemic period and are aggravated during restoration of blood flow. Predominant lesions
or alterations associated with intestinal I-R injuries include alterations in cell membrane
permeability, tissue edema, inflammatory cell influx, hemorrhage and necrosis of the
intestinal wall (Moore et al., 1994). Horses with intestinal compromise from prolonged or
severe ischemia secondary to strangulation obstruction probably do not undergo a
relevant reperfusion injury. However, horses with ischemia of less severity or shorter
duration may be susceptible to reperfusion injury. There is experimental evidence to
show that the small intestine and large colon of horses are capable of undergoing I-R
injury (Horne et al., 1994; Moore et al., 1994;). Moore et al. (1994) showed
histopathologic evidence of reperfusion injury in the large colon of adult horses after
reestablishment of colonic arterial blood flow after 3 hrs of low-flow ischemia. In horses,
even after surgical correction of volvulus or strangulation obstruction, horses may
recover well for a few hours and then begin to deteriorate due to continued ischemia or
reperfusion injury (Moore et al., 1994).
Provost et al. (1991) showed that after correction of a 1-hr 720º experimental
large colon torsion in ponies, colonic blood flow increased above ischemic flow, but
remained well below the preocclusion flow. Similar observations of reduced blood flow
below pre-ischemic values after the release of arteriovenous occlusion was shown in the
large colon of horses (Wilkins et al., 1994). This observed reduction in blood flow after
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correction of experimentally-induced large colon volvulus (Provost et al., 1991) or
combined arteriovenous occlusion (Wilkins et al., 1994) in ponies was attributed to
vasoactive mediators released during obstructive disorders.
2.6.3 Mechanism of I-R injury
Several mechanisms seem to be essential for the development of post-ischemic
lesions of the gut. The injury is triggered by both molecular and enzyme-mediated
mechanisms (Figure 2.4). Initially, oxygen radicals initiated by the hypoxanthinexanthine oxidase system are the molecular triggers. Second, activation of phospholipase
A2, possibly due to influx of calcium, constitutes an enzymatic trigger. This deleterious
cascade is perpetuated by phospholipids-derived mediators and neutrophils.
2.6.3.1 Production of Oxygen Free Radicals
Under normal conditions, cellular oxidative phosphorylation involves a 4-electron
reduction of oxygen to water (Flaherty and Weisfeldt, 1988). This occurs as a series of
reactions resulting in the formation of superoxide anion and hydroxyl radical (OH˙). The
superoxide anion and OH˙are highly reactive free radicals that can react with cell
membranes and cause loss of cellular integrity and tissue damage (Flaherty and
Weisfeldt, 1988). Further, hydrogen peroxide (H2O2), which is not highly reactive, can be
converted into OH- by ferrous iron, which is made available from the superoxidemediated conversion of ferric to ferrous iron (Flaherty and Weisfeldt, 1988). Naturally
occurring antioxidants protect the tissues from the oxygen free radicals (OFRs) formed
during normal cellular metabolism. Endogenous antioxidants include enzymatic
antioxidants (superoxide dismutase, catalase and glutathione peroxidase) and nonenzymatic antioxidants (alpha-tocopherol, ascorbate and beta-carotene).
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During reoxgyenation of ischemic tissues, rapid formation of these radicals can
overwhelm the protective effects of endogenous antioxidants, resulting in further injury.
During ischemia, several events occur that set the stage for OFR production upon
reperfusion. Hypoxanthine accumulates in endothelial cells and in intestinal mucosal
cells and is catalyzed by xanthine oxidase (XO), an enzyme present in the cytosol, to
form xanthine and uric acid, with the generation of a superoxide radical. Increased
intracellular Ca2+ during ischemia, in conjunction with calpain, converts xanthine
dehydrogenase (XDH) to XO (Cohen, 1989). The hypoxanthine that accumulates during
ischemia provides large amounts of substrate for superoxide synthesis during
reoxygenation. Superoxide radicals are converted to H2O2 by endogenous superoxide
dismutase.
The synthesis of OH radicals through iron-dependent mechanisms is called the
Haber-Weiss reaction (O2. + H2O2. → OH·). During reoxygenation, the production of
free radicals such as OH overwhelms the endogenous antioxidant systems. These
hydroxyl radicals initiate cellular damage via lipoperoxidation and release of
phospholipids-derived mediators (leukotriene-B4 and platelet activating factor), which
are chemoattractants of neutrophils. Thus the overabundance of OFRs produced during
reperfusion leads to oxidant-induced tissue injury (Flaherty and Weisfeldt, 1988).
2.6.4 Mucosal Injury
Studies have shown strangulation obstruction in adult horses can induce gross
changes in the intestinal wall, necrosis of villus tips in strangulated small intestinal
segment, and to a lesser degree, in the non-strangulated jejunum orad to the strangulation
(Dabareiner et al., 1993). Experimentally-induced large colon ischemia causes
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Figure 2.4 Proposed etiopathogensis of ischemia-reperfusion injury. During ischemia,
hypothanthine accumulates in epithelial cells and intestinal mucosal cells simultaneous
with the conversion of xanthine dehydrogenase (XDH) to xanthine oxidase (XO). On
reperfusion, hypoxanthine is metabolized by XO. The superoxide and hydrogen peroxide
(H2O2) react in the presence of an Fe3+ catalyst to form the hydroxyl ion (OH-), which
initiates lipoperoxidation, and causes release of phospholipid-derived mediators (LTB4,
PAF), which are chemoattractants of neutrophils. On adhesion to the endothelium,
neutrophils release elastase and lactoferrin, causing extravasation. O2 is converted to O2-,
which is further metabolized to H2O2 by nicotinamide adenine nucleotide phosphate
(NADPH) oxidase. Myeloperoxidase then catalyzes the reaction of H2O2 and a chloride
ion resulting in toxic hypochlorous acid (HOCl). [Redrawn with the permission of Moore
et al., 1995]
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accumulation of fluid in the intestinal wall, lumen and mesentery and the serosa becomes
dark purple (Snyder et al., 1988). The thickening of the intestinal wall is due to
hemorrhage, edema and congestion (Snyder et al., 1989). The observed changes are
attributed to increased capillary hydrostatic pressure associated with venous obstruction
and increased microvascular permeability due to inflammatory cell infiltration and
mediator release during ischemia.
During small intestinal hemorrhagic strangulation obstruction, fluid sequesters in
the subepithelial space, and the epithelium separates from the underlying attachment to
the basement membrane at the villus tip (White, Moore, Trim, 1980). Sloughing of
epithelial cells develops due to severe intracellular alterations. The villi are completely
denuded in 3 hrs, and the villi contract to the levels of the crypts (Freeman et al., 1988).
During various periods of ischemia, complete necrosis of the mucosal epithelium extends
to the base of the crypt, which occurs by 4 to 5 hrs, and by 6 to 7 hrs degeneration
extends beyond the muscular layer (White, Moore, Trim, 1980). Combined ischemia and
reperfusion of 2-hrs duration induces moderately severe mucosal injury in the equine
jejunum, characterized principally by disruption of enterocyte attachment from the
basement membrane to the lamina propria (Arden et al., 1990). Eventually, the
progression of mucosal epithelial injury leads to mucosal necrosis, with disruption of the
mucosal barrier, allowing migration of luminal bacteria and endotoxin into the systemic
circulation.
2.7 Role of ET-1 in the Pathophysiology of The Gastrointestinal Tract Disorders
The role of ET-1 in etiopathogensis of various disorders such as ischemia, I-R
injury, vasospasm, motility disorders and endotoxic shock is well documented in several
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species (Murch et al., 1992; Chou et al., 1995; Wanecek et al., 1997; Soda et al., 1999;
Tekin et al., 1999; Ozel et al., 2001). High concentrations of circulating plasma ET-1
concentrations and increased tissue ET-1 expression have been shown in these
pathological conditions, suggesting a direct or indirect role of ET in the pathogenesis of
these disorders. The observed increase in plasma ET-1 is believed to be exacerbated by
the reduced intestinal blood flow caused by increased vascular resistance, resulting in
ischemia and I-R injury.
Endothelial damage occurs in the colonic vasculature of the large colon and small
intestine of horses subsequent to I-R and is further injured by endotoxemia (Henninger et
al., 1992; Dabareiner et al., 1993). The sustained reduction in blood flow and/or
reperfusion injury may be attributable to the release of endothelial-derived contractile
factors (EDCF), such as ET-1, from the damaged vasculature or due to imbalance
between ET-1 and NO release.
Horses with strangulation obstruction (low-flow states) and endotoxemia have
increased levels of circulating IL-1, catecholamines, TNF-α and thrombin, which are
known to cause increased ET-1 synthesis and secretion (Barton and Callatos, 1999;
Morris, 1991). The potent contractile effects of exogenous ET-1 were characterized in
isolated, endothelium-intact and-denuded colonic blood vessels of horses (Venugopal et
al., 2001). This dose-dependent contraction of colonic vasculature was abolished by prior
administration of ET receptor antagonists. Thus, the observed reduction in blood flow
and I-R injury associated with surgical correction in intestinal strangulation obstruction in
horses may be due to increased circulating levels of ET-1, altering vasomotor tone and
reducing blood flow.
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Endothelin-1 promotes leukocyte rolling, expression of adhesion molecules, platelet
aggregation, thromboxane formation, superoxide generation and arachidonic acid release
(Boros et al., 1998). In rats, ET-1 induces a dose-dependent increase in vascular
permeability through the activation of ETA receptors due to disruption of the endothelial
barrier (Filep et al., 1991). Use of ET receptor antagonists decreased ET-induced
endothelial-leukocyte interactions and other pro-inflammatory responses (Boros et al.,
1998). Wolfard et al. (1999) found that ETA receptor antagonism attenuated small bowel
injury due to I-R in dogs. This clearly suggests that activation of ET receptors is a major
factor in the mediation of ischemia and I-R injury. Another possibility is that ET-1
induced vasoconstriction leads to the no-reflow phenomenon or post-ischemic
hypoperfusion.
Endothelin immunoreactivity is over-expressed or up-regulated with various
inflammatory conditions, low-oxygen tension, hypoxia, and peritonitis (Murch et al.,
1992; Dikranian et al., 1994; Chou et al., 1995). Hypoxia induces an increase in ET-1
immunoreactivity in large intestinal endothelial and epithelial cells of rats (Dikranian et
al., 1994; Chou et al., 1995). The ET-1 immunolabelling was identified as single particles
in normoxic rat large intestine, but only in low levels; this labelling was predominantly
confined to the cytoplasm of endothelial cells of mucosal arterioles and post-capillary
venules. Hypoxia was associated with increased ET-1 immunolabelling in the mucosal
vasculature and epithelium of the rat large intestine.
Endothelin also has potent contractile activity in non-vascular smooth muscle
such as vas deferens, uterus, trachea, stomach and ileum of various species (Takahashi et
al., 1990; Rae, Calixto, D’Orleans-Juste, 1995). Abundant ET-1 binding sites have been
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found in the stomach, intestine and colon of rats, and other species (Takahashi et al.,
1990; Koseki et al., 1989). All three endothelin isoforms (ET-1, -2 and -3) and both
receptor types (ETA and ETB) are expressed throughout the gastrointestinal tract, where
they likely have some physiological role. The ET-1 action mediated by the ETA receptor
unmasks the inhibitory ET-1 action mediated through the ETB receptor. Repetitive
peristalsis in fluid-perfused isolated segments of guinea pig small intestine showed that
propulsive motility is mediated by ETA receptors on enteric neurons, whereas its action is
masked by activation of ETB receptors (Shahbazian and Holzer, 2000).
Several studies suggest ET-1 as a potential candidate in the pathophysiology of
strangulation obstruction and other disorders. Endothelin-1 is synthesized in the vascular
endothelium (Yanagisawa et al., 1988) and causes contraction of intestinal vasculature in
horses (Venugopal et al., 2001). Furthermore, ET receptors are present in both vascular
and non-vascular smooth muscle of the gastrointestinal tract in horses and other species.
Although it is highly unlikely that ET-1 alone can induce intestinal damage, it may act
synergistically with other endogenous mediators in the pathogenesis of gastrointestinal
tract disorders. Overall, its potent vasoconstrictor nature, widespread distribution and
synthesis in various organs, its regulatory role with NO in regulating blood flow and
vasomotor tone, and interrelationships with inflammatory mediators suggest its potential
involvement in these disorders.
2.8 Methods of Quantification of Equine Endothelin-1
Measurement of plasma or tissue expression of ET-1 has been achieved by
various techniques such as radioimmunoassay (RIA), enzyme-linked immunosorbent
assay (ELISA), competitive polymerase chain reaction and by real time polymerase chain
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reaction (TaqMan assay) (Benamou et al., 1998; Uchide et al., 2000; Seligman et al.,
2000). Even though most techniques have advantages and disadvantages, the
quantification of ET-1 poses a unique problem, due to its inherent nature and its mode of
secretion into the circulation. Further, numerous problems are associated with
measurement and interpretation of the measured ET-1, which can be due to either ET-1
itself and/or the techniques used.
Circulating concentrations of ET-1 are only a few pg/mL and any assay designed
to measure the ET-1 must be quiet sensitive. The circulating half-life of ET-1 is 5-7 min
and it is rapidly cleared mainly through the lungs and kidneys. This depends on a variety
of factors such as renal or lung function, enzymatic degradation and the binding
properties of the circulating ET. Further, secretion of ET-1 is mostly abluminal (>80%)
so the measured plasma ET-1 simply reflects its synthesis and overspill. Commercially,
there is no anti-equine ET antibody or sera available for the measurement of ET-1.
Endothelin is highly conserved among mammalian species and a high (>80%) degree of
homology at the nucleotide level among different species, including bovine, rat, human
and pig. The ET-1 is the most important and active isoform in blood and is usually the
one measured. Cross-reactivity of ET-1 to ET-2 and ET-3 should be taken into
consideration while quantifying the plasma ET-1. Thus, there are a myriad of factors
involved in the measurement and interpretation of circulating ET levels.
2.8.1 Immunoassays
Measurement techniques such as RIA and ELISA are widely employed. Because
the circulating levels of ET are quite low, the plasma needs to be concentrated or
extracted before these assays. The extracting process might degrade the ET-1 and also the
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variation between and within assay may vary depending upon the technique and the
personnel involved (Morganti et al., 2000). The sensitivity of these assays should also be
considered. Even though most of the good immunoassays are sufficient to detect levels of
0.5 pg/mL, the sensitivity of the methods varies and usually falls in the range of 2-8
pg/mL (Goddard and Webb, 2000). The inter- and intra-assay variation are high, with
>10% having been reported, reducing the accuracy of the measurement (Morganti et al.,
2000). In addition, sampling and type of sample (icteric, lipemic or hemolyzed) have also
been found to affect the measurement of the ET-1. Regardless of these problems, the RIA
is widely employed with careful interpretation and using more appropriate terms like
‘ET-like immunoreactivity’.
2.8.2 Polymerase Chain Reaction
Polymerase chain reaction (PCR) is a powerful tool for amplifying specific DNA or
RNA targets. Apart from cloning and sequencing DNA, PCR is used in a variety of
scientific applications. The exquisite sensitivity and specificity of the PCR reaction (it
can detect and amplify even one DNA molecule) renders it a unique and valuable
diagnostic tool in medicine. Various procedures such as quantitative PCR and southern
blots are used to quantify the PCR products. However, these methods are cumbersome
and labor intensive. Recently, techniques such as life cycler and TaqMan assays have
been used.
2.9 Statement of Hypotheses and Specific Objectives
2.9.1 Global Hypothesis
The major physiologic functions of the intestine are motility, secretion and
absorption, all of which are directly or indirectly controlled by blood flow. So any
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impairment in blood flow has a deleterious effect on gastrointestinal tract function.
Reduction in blood flow due to vasoconstrictor agents seems to be of primary importance
during various occlusive/non-occlusive disorders in horses. Studies have shown that the
progressive intestinal damage observed in colic during both pre- and post-operative
conditions could be due to increased levels of vasoconstrictor mediators, resulting in a
sustained reduction of blood flow. I hypothesize that this sustained reduction in intestinal
blood flow contributes to intestinal tract injury and is due to increased circulating levels
of ET-1 and that there will be increased ET-1 immunostaining in horses with intestinal
strangulation obstruction, compared with gastrointestinal segments from normal horses.
We also hypothesize that ET-1 will cause a concentration-dependent contraction of the
cecal smooth muscle of healthy horses. Our studies also included the identification of ET1 gene expression and immunohistochemical localization and distribution of ET-1 in the
gastrointestinal tract of clinically healthy horse and those with naturally acquired
intestinal strangulation obstruction. Additionally we characterized ET-1 response in the
equine gastrointestinal smooth muscle mediated by ETA and ETB receptors.
2.9.2 Specific Objectives
1. To determine basal circulating plasma ET-like immunoreactivity in healthy
horses.
2. To determine circulating plasma ET-like immunoreactivity in horses with
naturally acquired gastrointestinal tract disorders.
3. To investigate any relationship between circulating concentrations of plasma ETlike immunoreactivity and clinical and clincopathological variables and survival
of horses affected with naturally acquired gastrointestinal tract disorders.
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4.

To evaluate the presence and regional distribution of ET-1 like immunoreactivity
in various intestinal segments of healthy horses.

5. To determine and compare the alterations in intensity and distribution of ET-like
immunoreactivity in the intestinal segments collected from horses with naturally
acquired small intestinal and large colon strangulating obstruction with those from
healthy horses.
6. To identify the presence of the ET-1 gene expression in various segments of
gastrointestinal tract of healthy horses and those with naturally acquired intestinal
strangulation obstruction.
7. To determine the concentration-response relationship of ET-1 on cecal smooth
muscle and compare the responses with carbachol, a muscarinic agonist.
8. To determine ET receptor types involved in the ET-1 mediated smooth muscle
response in cecal smooth muscle by using specific ET receptor antagonists.
2.10 References
Anggard E, Galton S, Rae G, et al. The fate of radioiodinated endothelin-1 and
endothelin-3 in rat. J Cardiovasc Pharmacol 1989;13(Suppl 5):S46-S49.
Arai H, Hri S, Aramori I, et al. Cloning and expression of a cDNA encoding an
endothelin receptor. Nature 1990; 348:730-732.
Aramori I, Nakanishi S. Coupling of two endothelin receptor subtypes to differing signal
transduction in transfected Chinese hamster ovary cells. J Biol Chem 1992;267:1246812474.
Arden WA, Slocombe RF, Stick JA, et al. Morphologic and ultrastructural evaluation of
effect of ischemia and dimethyl sulfoxide on equine jejunum. Am J Vet Res 1990;
51(11):1784-1791.
Argenzio RA, Lowe JE, Pichard DW, et al. Digesta passage and water exchange in the
equine large intestine. Am J Physiol 1974;226:1035-1042.

48

Baker JR, Ellis CE. A survey of postmortem findings in 480 horses: 1958-1981. Equine
Vet J 1981;13:43-46.
Barclay WP, Foerner JJ, Phillips TN. Volvulus of the large colon in the horse. J Am Vet
Med Assoc 1980;177:629-630.
Barton MH, Collatos C. Tumor necrosis factor and interleukin-6 activity and endotoxin
concentration in peritoneal fluid and blood of horses with acute abdominal disease. J Vet
Intern Med 1999;13(5):457-464.
Benamou AE, Art T, Marlin DJ, et al. Effect of exercise on concentrations of
immunoreactive endothelin in bronchoalveolar lavage fluid of normal horses and horses
with chronic obstructive pulmonary disease. Equine Vet J 1998;30:92-95.
Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133-138.
Bennet HS, Luft JH, Hampton JC. Morphological classification of vertebrate blood
capillaries. Am J Physiol 1959;196:381-390.
Berti F, Rossoni G, Della Bella D, et al. Nitric oxide and prostacyclin influence coronary
vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc
Pharmacol 1993;22(2):321-326.
Bilkslager AT, Bowman KF, Levine JF, et al. Evaluation of factors associated with
posoperative ileus in horses: 31 cases (1990-1992). J Am Med Assoc 1994;205:17481752.
Blikslager AT, Roberts MC, Gerard MP, et al. How important is intestinal reperfusion
injury in horses? J Am Med Assoc 1997;211(11):1387-1389.
Boeckxstaens GE, Pelckmans PA, Herman AG, et al. Involvement of nitric oxide in the
inhibitory innervation of the human isolated colon. Gastroenterology 1993;104:690-697.
Bolger GT, Liard F, Garneau M, et al. Characterization of intestinal smooth muscle
responses and binding sites for endothelin. Can J Physiol Pharmacol 1992;70:377-384.
Boros M, Massberg S, Baranyi L, et al. Endothelin induces leukocyte adhesion in
submucosal venules of the rat small intestine. Gastroenterology 1998;114:103-114.
Borsum T. Biochemical properties of vascular endothelial cells. Virchows Archiv B Cell
Pathol 1991;60:279-286.
Brenner BM, Troy JL, Ballerman BJ. Endothelium-dependent vascular responses. J Clin
Invest 1989;84:1373-1378.
Burns GA, Cummings JF. Equine myenteric plexus with special reference to pelvic
flexure pace maker. Anat Rec 1991;230:341-350.

49

Burns GA, Cummings JF. Neuropeptide distributions in the colon, cecum, and jejunum of
the horse. Anat Rec 1993;236(2):341-350.
Casteels R, Droogmans G, Reaymaekers L. Distribution and exchange in electrolytes in
gastrointestinal smooth muscles. In: J.D. Wood, ed. Motility and circulation. Part I.
Second Ed. Betheda. American Physiological Society, 1989;141-162.
Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: Marked
elevations in patients with cardiogenic shock. Biochem Biophys Res Comm
1989;161(2):562-567.
Chou MC, Wilson MA, Spain DA, et al. Endothelin-1 expression in the small intestine
during chronic peritonitis. Shock 1995;4:411-414.
Cohen MV. Free radicals in ischemic and reperfusion myocardial injury: A selective
review. Ann Int Med 1989;111:918-931.
Collatos C, Romano S. Cecal impaction in horses: causes, diagnosis, and medical
treatment. Compend Contin Educ Pract Vet 1993;15:976-982.
Dabareiner RM, Snyder JR, Sullins KE, et al. Evaluation of the microcirculation of the
equine jejunum and ascending colon after ischemia and reperfusion. Am J Vet Res
1993;54(10):1683-1692.
Dabareiner RM, White NA. Large colon impaction in horses: 147 cases (1985-1991). J
Am Vet Med Assoc 1995;206(5):679-685.
Darien BJ, Stone WC, Dubiclzig RR, et al. Morphologic changes of the ascending colon
during experimental ischemia and reperfusion in ponies. Vet Pathol 1995;32:280-288.
Davenport AP, Nunez DJ, Hall JA, et al. Autoradiographical localization of binding sites
for porcine endothelin-1 in humans, pigs and rats: Functional relevance in humans. J
Cardiovasc Pharmacol 1989;13(S5):S166-S170.
Davies JV, Gerring El. Effect of experimental vascular occlusion on small intestinal
motility in ponies. Equine Vet J 1985;17:219-224.
Davies JV. Normal intestinal motility. In: Advances in Equine Abdominal Surgery.
1989:5(2):271-281.
de Nucci G, Thomas S, D’Orleans-Juste P, et al. Pressor effects of circulating endothelin
are limited by its removal in the pulmonary circulation and by the removal of
prostacyclin and endothelium derived relaxing factor. Proc Natl Acad Sci USA
1988;85:9797-9800.

50

Dikranian K, TomLinson A, Loesch A, et al. Increase in immunoreactivity to endothelin1 in the mucosal vasculature and epithelium of the large intestine during chronic hypoxia.
J Anat 1994;185( Pt 3):609-615.
Eades SC, Moore JN. Blockade of endotoxin –induced cecal hypoperfusion and ileus
with and alphha-2 antagonist in horses. Am J Vet Res 1993;54(4):586-590.
Emori T, Hirata Y, Ohta H, et al. Secretory mechanism of immunoreactive endothelin
production by cultured endothelial cells. Biochem Biophys Res Commun 1989;160:93100.
Fantone JC. Pathogenesis of ischemia-reperfusion injury: an overview. In: Zelencock
GB. ed. Clinical ischemic syndromes: Mechanisms and consequences of tissue injury. St.
Louis: The C.V. Mosby Company 1990; 137-145.
Fevang J, Ovrebo K, Ostgaard G, et al. Release of endothelin in strangulation obstruction
of the small bowel in pigs. J Surg Res 1998;79:77-84
Filep JG, Sirois MG, Rousseau A, et al. Effects of endothelin-1 on vascular permeability
in the conscious rat: Interactions with platelet-activating factor. Br J Pharm
1991;104:797-804.
Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and
the effects of ischemia on renal gene expression. J Clin Invest 1992;90:1023-1031.
Fischer AT, Meagher DM. Strangulating torsions of the equine large colon. Compend
Contin Ed Pract Vet 1986;8:S25-S31.
Flaherty JT, Weisfeldt ML. Reperfusion injury. Free Radic Biol Med 1988;5(5-6):409419.
Freeman DE, Cimprich RE, Richardson DW, et al. Early mucosal healing and chronic
changes in pony jejunum after various types of strangulation obstruction. Am J Vet Res
1988; 49:810-817.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of
arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
Gentilini P, La Villa G, Casini-Raggi V, et al. Hepatorenal syndrome and its treatment
today. Eur J Gastroenterol Hepatol 1999; 11(9):1061-1065.
Goddard J and Webb DJ. Plasma endothelin concentrations in hypertension. J
Cardiovasc Pharmaco. 2000;35(4 Suppl 2):S25-S31.

51

Grum CM. Cellular energetics. In: Zelencock GB. ed. Clinical ischemic syndromes:
Mechanisms and consequences of tissue injury. St. Louis: The C.V. Mosby Company
1990;47-62.
Guo X, Luo A, Xu S, et al. The protective effect of captopril during myocardial ischemia
and reperfusion and its mechanism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1998;
20(3):220-225(Abstract).
Guyton, AG. A Textbook of Medical Physiology.Ninth ed. Philadelphia. W.B.Saunders,
2000.
Haglund U, Lundgren O. Intestinal ischemia and shock factors. Fed Proc 1987;37:27292733.
Harrison IW. Equine large intestinal volvulus. A review of 124 cases. Vet Surg
1988;17:77-81.
Hebra A, Brown MF, McGeehin K, et al. The effects of ischemia and reperfusion on
intestinal motility. J Pediatr Surg 1993;28(3):362-365.
Hemsen A, Lundberg JM. Presence of endothelin-1 and endothelin-3 in peripheral tissues
and central nervous system of the pig. Regul Pept 1991;36(1):71-83.
Henninger DD, Snyder JR, Pascoe JR, et al. Microvascular permeability changes in
ischemia/reperfusion injury in the ascending colon of horses. J Am Vet Med Assoc
1992;201(8):1191-1196.
Hickey KA, Rubanyi GM, Paul RJ, et al. Characterization of a coronary vasoconstrictor
produced by cultured endothelial cells. Am J Physiol 1985;248:C550-C556.
Horne MH, Pascoe PJ, Ducharme NG, et al. Attempts to modify reperfusion injury of
equine jejunal mucosa using dimethyl-sulfoxide, allopurinol, and intraluminal
oxygenation. Vet Surg 1994;23:241-249.
Huskamp B. The diagnosis and treatment of acute abdominal conditions in the horse: the
various types and frequency as seen at the animal hospital in Hochmoor, in Proceedings.
Proc Equine Colic Res Symp 1982;261-272.
Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family three structurally
and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl
Acad Sci 1989;86:2863-2867.
Itoh Y, Yanagisawa M, Ohkubo S, et al. Cloning and sequence analysis of cDNA
encoding the precursor of a human endothelium-derived vasoconstrictor peptide
endothelin: Identity of human and porcine endothelin. FEBS 1988;231:440-444.

52

Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial
cells. Clin Exp Rheumatol 1997;15(2):163-167.
Kalia N, Pockley AG, Wood RF, et al. Effects of FK409 on intestinal ischemiareperfusion injury and ischemia-induced changes in the rat mucosal villus
microcirculation. Transplantation 2001;72(12):1875-1880
Kanse SM, Takahashi K, Lam H, et al. Cytokine stimulated endothelin release from
endothelial cells. Life Sci 1991;48:1379-1384.
Kasuya Y, Ishikawa T, Yanagisawa M, et al. Mechanism of contraction to endothelin in
isolated porcine coronary artery. Am J Physiol 1989;57:H1828-H1835.
King JN, Gerring EL. Detection of endotoxin in cases of equine colic. Vet Rec 1988;
123:269-271.
Kloog T, Sokolovsky M. Similarities in mode and sites of action of sarafotoxins and
endothelins. Trends Pharmacol Sci 1989;10:210-214.
Koh E, Morimoto S, Kim S, et al. Endothelin stimulates Na+/H+ exchange in vascular
smooth muscle cells. Biochem Int 1990;267:375-380.
Koseki C, Imai M, Hirata Y, et al. Autoradiographic distribution in rat tissues of binding
sites for endothelin: a neuropeptide. Am J Physiol 1989;56:R858-R862.
Kourembanas S, Marsden PA, McQuillan LP, et al. Hypoxia induces endothelin gene
expression and secretion in cultured human endothelium. J Clin Invest 1991;88:10541057.
Kruse-Elliot KT, Whorton AR, Olson NC. Role of lipid-derived mediators in tumor necrosis
factor-induced endothelin-1 release in vivo. Shock 1998:9(1):40-45.
Kurihara H, Yoshizumi M, Sugiyama T, et al. Transforming growth factor-β stimulates
the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res
Commun 1989;159:1435-1440.
Lee ME, Bloch KD, Clifford JA, et al. Functional analysis of the endothelin-1 gene
promotor. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem
1990;265:10446-10450.
Levin RI. Endothelins. New Engl J Med 1995;333(6):358-363.
Lin HY, Kaji EH, Winkel GK, et al. Cloning and functional expression of a vascular
smooth muscle endothelin-1 receptor. Proc Natl. Acad Sci USA 1991; 88:3185-3189.

53

Lowe JE, Sellers AF, Brondum J. Equine pelvic flexure impaction. A model used to
evaluate motor events and compare drug response. Cornell Vet 1980;70(4):401-412.
MacCumber MW, Ross C, Snyder SH. Endothelin in brain: Receptors, mitogenesis and
biosynthesis in glial cells. Proc Natl Acad Sci USA 1990; 87:2359-2363.
MacDonald MH, Pascoe JR, Stover SM, et al. Mortality rates associated with small
intestine and anastomosis in horses. Vet Surg 1989;18:415-423.
Malek A, Izumo S. Physiological fluid shear stress causes down regulation of endothelin1 mRNA in bovine aortic endothelium. Am J Physiol 1992;263:C389-C396.
Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNFα. Am J Physiol 1992;262:C854-C861.Masaki T. The endothelin family: An overview. J
Cardiovasc Pharmacol 2000;35(Suppl 2):S3-S5.
Masaki T. The endothelin family: An overview. J Cardiovasc Pharmacol 2000;35(Suppl
2):S3-S5.
Matsumoto H, Suzuki N, Onda H, et al. Abundance of endothelin-3 in rat intestine,
pituitary gland and brain. Biochem Biophys Res Commun 1989;164(1):74-80.
Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms
prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
Nature (Lond.) 1976;263:663-665.
Moore RM, Bertone AL, Muir WW, et al. Histopathologic evidence of reperfusion
injury in the large colon of horses after low-flow ischemia. Am J Vet Res 1994; 55:14341443.
Moore RM, Muir WW, Granger DN. Mechanisms of gastrointestinal ischemiareperfusion injury and potential therapeutic interventions: A review and its implications
in the horse. J Vet Int Med 1995;9:115-132.
Morganti A, Marana I, Airoldi F, et al. Plasma endothelin levels: a meaningless number?
J Cardiovasc Pharmacol 2000;35(Suppl2):S21-S23.
Morris DD, Moore JN, Crowe N, et al. Effect of experimentally induced endotoxemia on
serum interleukin-6 activity in horses. Am J Vet Res 1992;53:753-756.
Morris DD, Moore JN, Ward S. Comparison of age, sex, breed, history and management
in 229 horses with colic. Equine Vet J 1989;l7:129-132.
Morris DD. Endotoxemia in horses: A review of cellular and humoral mediators involved
in its pathogenesis. J Vet Int Med 1991;5(3):167-181.

54

Murch SH, Braegger CP, Sessa WC, et al. High endothelin-1 immunoreactivity in
Crohn’s disease and ulcerative colitis. Lancet 1992;339:381-385.
Ohnaka K, Takayangi R, Yamauchi T, et al. Identification and characterization of
endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res
Commun 1990;168:1128-1136.
Oktar BK, Gulpinar MA, Bozkurt A, et al. Endothelin receptor blockers reduce I/Rinduced intestinal mucosal injury: role of blood flow. Am J Physiol (Gastrointest Liver
Physiol) 2002;282(4):G647-G655.
Opgenorth TJ, Wu-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB
1992;18:408-412.
Ozel SK, Yuksel M, Haklar G, et al. Nitric oxide and endothelin relationship in intestinal
ischemia/reperfusion injury. Prostaglandins Leukot Essent Fatty Acids 2001;64:253-257.
Parry BW. Survey of 79 referral colic cases. Equine Vet J 1983;15:345-348.
Pascoe PJ, McDonell WN, Trim CM, et al. Mortality rates and associated factors in
equine colic operations–A retrospective study of 341 operations. Can Vet J 1983;24:7685.
Patel A, Kaleya RN, Sammartano RJ. Pathophysiology of mesenteric ischemia. Surg Clin
North Am 1992;72:31-41.
Pearson JD. Endothelial cell biology. Radiology 1991;179:9-14.
Pfeiffer CJ, MacPherson BR. Anatomy of gastrointestinal tract and peritoneal cavity. In
Equine Acute Abdomen. 1990.
Power RF, Wharton J, Zho Y, et al. Autoradiographic localization of endothelin-1
bindings sites in the cardiovascular and respiratory systems. J Cardiovasc Pharmacol
1989; 13(Suppl 5):S50-S56.
Provost PJ, Stick JA, Patterson JS, et al. Effects of heparin treatment on colonic torsionassociated hemodynamic and plasma eicosanoid changes in anesthetized ponies. Am J Vet
Res 1991;52(2):289-297.
Rae GA, Calixto JB, D’Orleans-Juste P. Effects and mechanisms of action of endothelins
on non-vascular smooth muscle of the respiratory, gastrointestinal and urogenital tracts.
A review. Regul Pept 1995;55:1-46.
Roger T, Ruckebusch Y. Colonic alpha 2-adrenoceptor-mediated responses in pony. J Vet
Pharmacol Ther 1987;10(4):310-318.

55

Ross MW, Donawick WJ, Sellers AF, et al. Normal motility of the cecum and right
ventral colon in ponies. Am J Vet Res 1986;47(8):1756-1762.
Ross MW, Rutkowski JA, Cullen KK. Myoelectric activity of the cecum and the right
ventral colon in female ponies. Am J Vet Res 1989;50(3):374-379.
Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry,
pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735.
Schusser GF, Scheidemann W, Huskamp B. Muscle thickness and neuron density in the
cecum of horses with chronic cecal impaction. Equine Vet J 2000 (Suppl);32:69-73.
Schusser GF, White NA. Morphologic and quantitative evaluation of the myenteric
plexuses and neurons in the large colon of horses. J Am Vet Med Assoc 1997;210: 928934.
Schwartz SJ, Stores EH. Principles of surgery. New York. McGraw-Hill Book Co.
1969;843-854.
Schweizer A, Valdenairre O, Nelbock P, et al. Human ECE-1: Three isoforms with
distinct subcellular localizations. Biochem J 1997; 28:871-877.
Seligman BG, Biolo A, Polanczyk CA, et al. Increased plasma levels of endothelin 1 and
von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care
2000;23(9):1395-1400.
Sellers AF, Lowe JE. Review of large intestinal motility and mechanisms of impactions
in the horse. Equine Vet J 1986;18:261-263.
Shahbazian A, Holzer P. Regulation of guinea pig intestinal peristalsis by endogenous
endothelin acting at ETB receptors. Gastroenterology 2000;119:80-88.
Shiba R, Yanagisawa M, Miyauchi T, et al. Elimination of intravenously injected
endothelin-1 from the circulation of the rat. J Cardiovas Pharmacol 1989;3(Suppl 5):98101.
Shinmi O, Kimura S, Sawamura T, et al. Endothelin is a novel neuropeptide: isolation
and sequence determination of endothelin-1 and endothelin-3 in porcine brain. Biochem
Biophys Res Commun 1989;164:587-593.
Simonson MS, Wann S, Mene P, et al. Endothelin stimulates phospholipase C, Na/H
exchange, c-fos expression and mitogenesis in rat mesangial cells. J Clin Invest
1989;83(2):708-712.

56

Simonson MS. Endothelins: multifunctional renal peptides. Phsyiol Rev 1993;73: 375411.
Snyder JR, Olander HJ, Pascoe JR, et al. Morphologic alterations observed during
experimental ischemia of the equine large colon. Am J Vet Res 1988;49(6):801-809.
Snyder JR, Pascoe JR, Olander HJ, et al. Strangulating volvulus of the ascending colon
in horses. J Am Vet Med Assoc 1989;195:757-764.
Snyder JR, Pascoe JR, Olander HJ, et al. Vascular injury associated with naturally
occurring strangulating obstructions of the equine large colon. Vet Surg 1990;19:446-455.
Snyder JR. The pathophysiology of intestinal damage: effects of luminal distention and
ischemia. Vet Clin North Am Equine Pract 1989;490-498.
Soda Y, El-Assal ON, Yu L, et al. Suppressed endothelin-1 production by FK506 and
cyclosporin A in ischemia/reperfusion of rat small intestine. Surgery 1999;125(1):23-32.
Southard JH. Temperature effects and cooling. In Zelenock GB, ed. Clinic ischemic
Syndromes. Mechanisms and consequences of tissue injury. St. Louis: The C.V. Mosby
Company 1990;303-325.
Stanghellini V. Pseudoobstruction syndromes. In: Baillere’s Clinical Gastroenterology,
London, 1988;2(1):225-254.
Takahashi A, Tomomas T, Kaneko H, et al. Intestinal motility in an in vivo rat model of
intestinal ischemia-reperfusion with special reference to the effects of nitric oxide on the
motility changes. Pediatr Gastroenterol Nutr 2001;33(3):283-288
Takahashi K, Jones PM, Kanse SM, et al. Endothelin in gastrointestinal tract: Presence of
endothelin like immunoreactivity, endothelin-1 messenger RNA, endothelin receptors,
and pharmacological effect. Gastroenterology 1990;99(6): 1660-1667.
Takahashi M, Matsushita Y, Itjima Y, et al. Purification and characterization of
endothelin-converting enzyme from rat lung. J Biol Chem 1993;268:21394-21398.
Takayanagi R, Ohnaka K, Takasaki C, et al. Multiple subtypes of endothelin receptors in
human and porcine tissues: characterization by ligand binding, affinity labeling, and
regional distribution. J Cardiovasc Pharmacol 1991; 17(Suppl7):S127-S130.
Tekin E, Taneri F, Ersoy E, et al. Ileal and colonic contractions by endothelin-1 in
experimentally induced paralytic ileus in rats. Gen Pharmacol 1999;32:631-635.
Tinker MK, White NA, Lessard P, et al. Prospective study of equine colic incidence and
mortality. Equine Vet J 1997;29(6):448-453.

57

Turner AJ, Murphy LJ. Molecular pharmacology of endothelin converting enzymes.
Biochem Pharmacol 1996;51(2):91-102.
Uchide T, Adur J, Fukamachi T, et al. Quantitative analysis of endothelin-1 and
vasoactive intestinal contractor/endothelin-2 gene expression in rats by real-time reverse
transcriptase polymerase chain reaction. J Cardiovasc Pharmacol 2000;36(5 Suppl 1):S5S8.
Van Hoogmoed L, Snyder JR, Pascoe JR, et al. Evaluation of uniformity of
morphological injury of the large colon following severe colonic torsion. Equine Vet J
2000; Suppl 32:98-100.
Venugopal CS, Holmes EP, Koch CE, et al. In vitro pharmacologic effect of two
endothelin-1 antagonists on equine colonic arteries and veins. Am J Vet Res
2001;62(2):154-159.
Wagner OF, Vierhapper H, Gasic S, et al. Regional effects and clearance of endothelin-1
across pulmonary and splanchnic circulation. Eur J Clin Invest 1992;22:277-282.
Wanecek M, Oldner A, Rudehill A, et al. Cardiopulmonary dysfunction during porcine
endotoxin shock is effectively counteracted by the endothelin receptor antagonist
bosentan. Shock 1997;7(5):364-370.
Weitzberg E, Lundberg JM, Rudehill A, et al. Elevated plasma levels of endothelin in
patients with sepsis syndrome. Circ Shock. 1991;33:222-227.
Weems, WA. Intestinal wall motion, propulsion, and fluid movement: trends toward a
unified theory. Am J Physiol 1982;243(3):G177-G188
White NA, Dabareiner RM. Treatment of impaction colics. Vet Clin North Am Equine
Pract 1997;13(2):243-259.
White NA, Moore JN, Trim CM. Mucosal alterations in experimentally induced small
intestinal strangulation obstruction in ponies. Am J Vet Res 1980;41(2):193-198.
White NA. Epidemiology and aetiology of colic. In: The Equine Acute Abdomen. Ed:
N.A. White, Lea & Febiger, Philadelphia.1980;178-184.
White NA. Pathophysiology and principles of therapy: Pathophysiology of obstruction,
strangulation and strangulation/obstruction ischemia. In: Colahan PT, Mayhew IG, Merrit
AJ., Moore JN. Eds. Equine medicine and surgery, Goleta, CA: American Veterinary
Publications: 1990:490-498.
Wilkins PA, Ducharme NG, Lowe JE, et al. Measurement of blood flow and xanthine
oxidase activity during postischemic reperfusion of the large colon of ponies. Am J Vet
Res 1994;55:1168-1177.

58

Wilson DV, Patterson JS, Stick JA, et al. Histologic and ultrastructural changes after
large colon torsion, with and without use of a specific platelet activating factor antagonist
(WEB 2086), in ponies. Am J Vet Res 1994;55:681-688.
Wolfard A, Vangel R, Szalay L, et al. Endothelin-A receptor antagonism improves small
bowel graft perfusion and structure after ischemia and reperfusion. Transplantation
1999;68(9):1231-1238.
Woods M, Bishop-Bailey D, Pepper JR, et al. Cytokine and lipopolysaccharide
stimulation of endothelin-1 release from human internal mammary artery and saphenous
vein smooth-muscle cells. J Cardiovasc Pharmacol 1998;31(Suppl 1): S348-S450.
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide
produced by vascular endothelial cells. Nature 1988;332(31):411-415.
Yang GC, Croaker D, Zhang AL, et al. A dinucleotide mutation in the endothelin-B
receptor gene is associated with lethal white foal syndrome (LWFS); a horse variant of
Hirschsprung disease. Hum Mol Genet 1998;7(6):1047-1052
Yoshizumi M, Kurihara H, Morita T, et al. Interleukin-1 increases the production of
endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun 1990;
166:324-329.
Zhang XF, Iwamuro Y, Okamoto Y, et al. Endothelin-1-induced contraction of rat
thoracic aorta depends on calcium entry through three types of calcium channel. J
Cardiovasc Pharmacol 2000;36(5 Suppl 1):S105-S106.

59

CHAPTER 3
PLASMA CONCENTRATIONS OF ENDOTHELIN-LIKE
IMMUNOREACTIVITY IN HEALTHY HORSES AND HORSES WITH
NATURALLY ACQUIRED GASTROINTESTINAL TRACT DISORDERS*

*Reprinted with the permission from Am J Vet Res
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3.1 Introduction
Gastrointestinal tract disease (colic) is the leading cause of death in adult horses
(Baker and Ellis, 1981). Although mortality rates vary among studies, a substantial number
of horses with large-colon strangulating obstruction failed to survive despite advances in
equine medicine and surgery (Phillips and Walmsley, 1993). Colonic blood flow remains
significantly less than baseline values for at least 4 hours after correction of experimentallyinduced complete arteriovenous occlusion of the large colon in ponies (Wilkins et al., 1994).
Sustained reduction of intestinal blood flow after surgical correction is postulated as a cause
for the progression of mucosal injury resulting from a continuation of ischemic injury
associated with microvascular thromboses, splanchnic vasoconstriction or the resulting
cascade of events related to restoration of blood flow (Moore, 1997).
Endothelium synthesizes and releases vasorelaxing (eg, nitric oxide [NO],
prostacyclin) and vasoconstricting (eg, endothelin [ET], prostaglandins) substances that
regulate vasomotor tone (Katusic and Shepherd, 1991; Shepherd and Katusic, 1991). Several
intrinsic vasoregulatory mechanisms control tissue blood flow. Reduced blood flow after the
correction of colonic volvulus could occur secondary to the generation of endogenous
vasoconstrictor substances that induce contraction of the colonic vascular smooth muscle.
Thus, sustained hypoperfusion may be mediated by a disruption in the balance between
endothelium-derived vasoactive substances. For example, a decrease in nitric oxide (NO)
and/or and an increase in ET-1 could lead to increased intestinal vascular resistance (Moore
et al., 1995; Turk, 1998).
Endothelins are a family of peptides (ET-1, ET-2, ET-3 and vasoactive intestinal
contractor peptide) that exert numerous biological and pathophysiologic effects by binding
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to ETA or ETB receptors (Inoue et al., 1989; Saida, Mitsui, Ishida, 1989). Endothelins, the
most potent vasoconstrictors known, are synthesized in several tissues where they act to
mediate or modulate vasomotor tone, cell proliferation and hormone synthesis (Levin, 1995).
Production of ET-1 by endothelial cells increases during periods of reduced blood flow and
hypoxia in canine vascular endothelium (Rubanyi and Polokoff, 1994). In addition,
circulating concentrations of ET increase in several species during certain pathological
conditions such as endotoxemia, cardiogenic shock, and asthma (Myhre et al., 1993; Takao
et al., 1994; Cernacek and Stewart, 1989). The sustained hypoperfusion reported after
arteriovenous occlusion of the large colon in horses (Moore, 1997) could thus be mediated
by increased synthesis of ET-1 in the intestinal vasculature.
We hypothesized that ET, and specifically ET-1, may play a central role in
regulating regional blood flow in the gastrointestinal tract of horses, particularly during
pathological conditions such as intestinal strangulation obstruction and low-flow states.
The purposes of the study reported here were to measure and compare plasma
concentrations of ET-like immunoreactivity between healthy horses and those with
naturally acquired gastrointestinal tract disease and to investigate the relationship
between plasma ET-1 like inmmunoreactivity concentrations and clinical and clinicopathologic variables and survival in affected horses.
3.2 Materials and Methods
3.2.1 Animals
This study was approved by the Clinical Animal Care and Use Committee of
Louisiana State University. Horses of various light breeds ranging in age from 1 to 24 years
(median,7.5 yrs) were used. Control horses (n =29) were determined to be healthy on the
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basis of medical history and results of a thorough physical examination and clinical
evaluation. Affected horses (n=142) were those admitted to the Veterinary Teaching
Hospital at Louisiana State University because of gastrointestinal tract disorders. The
magnitude and cause of abdominal pain in affected horses was assessed by a thorough
physical examination and clinical evaluation. Temperature, respiratory rate, heart rate,
capillary refill time, mucous membrane color, and degree and duration of signs of abdominal
pain were recorded. For the purposes of this study, we categorized all horses into 1 of 10
groups. Group 1 (n = 29) comprised the healthy control horses. Group 2 (n = 6) consisted of
horses with a large intestinal strangulation obstruction (ie, large-colon volvulus and
cecocolic intussusceptions). Group 3 (n = 26) comprised affected horses with simple
obstruction of the large intestine (ie, impactions, cecal and colon displacements,
enterolithiasis). Group 4 (n = 12) comprised horses with a small-intestinal strangulating
obstruction. Group 5 (n = 9) comprised horses with a simple obstruction of the small
intestine (ie, ileal impaction). Group 6 (n = 12) and 7 (n = 8) consisted of horses with large
and small intestinal inflammatory bowl disease, respectively (ie, enterocolitis and anterior
enteritis, respectively). Group 8 (n = 13) consisted of horses with peritonitis, gastric rupture
or cecal perforation), Group 9 (n= 11) consisted of horses with gastric disorders (ie, ulcers,
impactions), and Group 10 ( n =45) consisted of horses with idiopathic gastrointestinal tract
disorders (ie, tympany or undiagnosed medical colic). Affected horses were assigned to a
group on the basis of the clinical diagnosis made from the results of clinical,
clinicopathologic, and where applicable, surgical and postmortem examinations.
3.2.2 Sample Collection
Blood samples were obtained from control horses and affected horses immediately of
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admission to the Veterinary Teaching Hospital and prior to the initiation of treatment. Blood
(10 ml) was collected via jugular venipuncture into prechilled collection tubes containing
EDTAa (500 kU/ml) and aprotininb (1 mg/ml). Samples were kept cold and centrifuged
within a few minutes of collection at 1,500 X g for 10 in a refrigerated (4˚C) centrifuge.
Plasma was then transferred into plastic tubes and stored at –70˚C until assayed. Additional
blood samples (3 ml) were collected into tubes containing EDTA for determination of CBC
and plasma fibrinogen determination and into tubes containing heparin for plasma
biochemistry analyses, including determination of creatinine concentration.
3.2.3 Measurement of Plasma ET-Like Immunoreactivity
Plasma ET-like immunoreactivity was quantified by use of a radioimmunoassayc
designed to measure ET-1 concentration in human plasma. The antibody used in this assay
principally recognizes human ET-1. However, the manufacturer reports that the antibody has
67 and 84 % cross-reactivity with human ET-2 and ET-3, respectively. Before assaying
plasma samples collected from control and affected horses, the assay was validated for use
with equine plasma. Recovery of ET-like immunoreactivity was determined by adding
known amounts of synthetic human ET-1 to pooled plasma from clinically normal horses.
Concentrations of ET in multiple replicates of spiked samples were measured within and
between assays to determine intra-and interassay variations, respectively.
To prepare plasma samples for the assay, they were thawed and extracted according
to the manufacturer’s recommended protocol by use of reverse-phase columns.d Prior to
extraction, columns were activated with 5 ml of 100% methanol, washed with 5 ml of
deionized water, and pre-treated with 5 ml of 4% acetic acid in distilled water; plasma
samples were acidified by mixing with an equal volume of 4% acetic acid in distilled water.
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After the addition of acidified plasma samples (1.5 ml) to pretreated columns, columns were
washed with 25% ethanol in distilled water, and ET was eluted with 4% acetic acid in a
solution of 86% ethanol in distilled water. The eluant was evaporated to complete dryness in
a 37˚C water bath under a stream of clean, dry nitrogen gas. Dried extracts were
reconstituted in 0.5 ml of assay buffer (borate buffer, pH 8.4).
Standard curves for the radioimmunoassay were prepared by the use of synthetic
human ET-1 according to the manufacturer’s guidelines. Each standard and extracted sample
was assayed in duplicate. Rabbit 125I –labeled ET-1 tracer and rabbit anti-endothelin
antiserum were added to each extracted sample and incubated for 18 hrs at 4˚C. A donkey
anti-rabbit cellulose precipitant was added to each tube and was incubated at room
temperature (20 to 22˚C) for 30 minutes. Tubes were then centrifuged at 2,000 X g for 15
minutes. The supernatant containing unbound 125I-labeled ET-1 was separated from the
pellet (containing antibody-bound 125I-labeled ET-1) by vacuum aspiration. Radioactivity in
the pellet was counted in a gamma counter for 2 minutes. Concentrations of ET-like
immunoreactivity in extracted plasma samples were determined by extrapolation from a
cubic spline standard curve.
3.2.4 Statistical Analyses
Continuous variables considered in the statistical analyses included plasma
concentrations of ET-like immunoreactivity, heart rate, total plasma protein and creatinine
concentration, PCV, platelet and neutrophil counts, WBC, durations of signs of pain, and
outcome (ie, survival vs nonsurvival). Continuous data were summarized by the use of
median, mean (± SD), and range.
Data was tested for normality by use of the Shapiro-Wilk statistic, with normality
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determined by failure to reject the null hypothesis at P < 0.05. Many variables did not
follow a normal distribution. Thus, continuous data were compared between control and
affected horses by use of the Kruskall-Wallis test for comparison of multiple groups of
ranked data. When a significant difference (P < 0.05) was detected, selected ad hoc
comparisons were made by the use of the Kruskall-Wallis procedure and by correcting
the significance level for the number of comparisons to maintain a type I error at 0.05.
For affected horses, an association between ET-like immunoreactivity and other
continuous variables was explored by use of stepwise linear regression. Variables were
maintained in the regression equation at P < 0.05. Pearson’s correlation coefficients
were calculated for the variables in the model. In addition, associations between survival
and both the continuous variables and the categorical groupings were explored by use of
logistic regression. Any horse that died or was euthanatized after a diagnosis was made
was assigned to the nonsurvival group. Stepwise selection of variables was performed,
with variables maintained in the model if the Wald statistic was significant at P < 0.05.
The 95% confidence interval (CI) of the conditional odds ratio for the variables included
in the model was calculated, and variables whose CI excluded 1 were considered
significant. All analyses were performed with the use of computer software programs.e
3.3 Results
3.3.1 Validation Assay
Mean percentage recovery of ET-1 recovered was 80% (range, 64 to 102%). Interassay and intra-assay variation were < 5% and 10%, respectively. The lowest detectable limit
was 0.1 pg/ml of ET-like immunoreactivity/ml of plasma.
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3.3.2 Plasma Concentrations of ET-Like Immunoreactivity
Median plasma concentrations of ET-like immunoreactivity were significantly
greater in horses with various gastrointestinal tract disorders, compared with healthy horses
(Table 3.1). In affected horses, the greatest median values for the ET-like immunoreactivity
were observed for horses with large intestinal strangulating obstruction (median, 10.02
pg/ml; rang, 3.8 to 22.62 pg/ml), peritonitis (9.19 pg/ml, 7.9 to 25.83 pg/ml), and
enterocolitis (8.89 pg/ml, 6.30 to 18.36 pg/ml).
3.3.3 Results of Clinical, Hematologic, and Biochemical Analyses
Packed cell volume (PCV), platelet count, heart rate, and plasma creatinine
concentration were slightly greater, and WBC and neutrophil count were slightly lower in
affected horses, compared with healthy horses (P>0.05). However, none of these differences
were statistically significant. In addition, none of the other clinical, hematologic, or
biochemical variables differed significantly between healthy and affected horses.
3.3.4 Association Between Plasma ET-Like Immunoreactivity and PCV and
Duration of Signs of Pain
Considering results from all affected horses, a significant association was found
between the plasma concentration of ET-like immunoreactivity and PCV and duration of
signs of pain (Figures 3.1 and 3.2). However, when these variables were considered
separately, the positive correlation was only modest (PCV, r =0.344; duration of signs of
pain, r = 0.216). Correlation increased when both PCV and duration of pain were added
to the regression model (r = 0.407). No other variables were significantly associated with
plasma ET-like immunoreactivity concentration.

67

Table 3.1 Plasma concentrations of endothelin-(ET)- like immunoreactivity in healthy
horses and horses with naturally acquired gastrointestinal tract disorders.
Group (n)

ET-like immunoreactivity (pg/ml)
_____________________________
Median
Range

Healthy (29)
LI strangulating obstruction (6)
LI simple obstruction (26)
SI strangulating obstruction (12)
SI simple obstruction (9)

1.8a
10.02c
3.97bc
5.53bcd
6.14bcd

1.09-3.12
3.8-22.62
3.27-8.01
1.72-9.48
4.97-9.70

Enterocolitis (12)
Anterior enteritis (8)
Peritonitis (13)
Gastric disorders (11)
Idiopathic colic (45)

8.89bcd
3.29bc
9.19cd
4.72bd
6.24bc

6.30-18.36
1.06-7.23
7.89-25.83
3.51-7.20
3.62-9.67

LI = Large intestinal. SI = Small intestinal
a-d
Median values with different superscript letters are significantly (P < 0.05) different.
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Figure 3.1 Packed cell volume versus plasma concentrations of endothelin- (ET)-like
immunoreactivity in 142 horses with naturally acquired gastrointestinal tract disorders.
The association between the 2 variables was significant (P <0.01), but the variables were
only modestly positively correlated (r = 0.344).
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Figure 3.2 Duration of signs of abdominal pain versus plasma concentrations of endothelin(ET)-like immunoreactivity in 142 horses with naturally acquired gastrointestinal tract
disorders. The association between the 2 variables was significant (P < 0.01), but the
variables were only modestly positively correlated (r = 0.216).
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3.3.5 Association Between Outcome, ET-Like Immunoreactivity and PCV
Logistic regression analysis revealed a significant association between outcome
(survival vs non-survival) and plasma concentration of ET-like immunoreactivity (odds
ratio, 0.942; 95% CI, 0.890 to 0.998) and PCV (0.945, 0.896 to 0.996) (Figure 3.3).
Survival was best explained by addition of both variables (ET-like immunoreactivity and
PCV) to the logistic model. No other variables were significantly associated with
outcome.
3.4 Discussion
Results of our study indicate that the circulating concentration of ET-like
immunoreactivity is increased in horses with gastrointestinal tract disorders, compared with
healthy horses. Plasma ET-like immunoreactivity in 29 healthy horses ranged from 1.09 to
3.2 pg/ml, which is in agreement with values reported previously for horses (Benamou, et al.,
1998). Within the affected group, median plasma concentration of ET-like immunoreactivity
was greatest in horses with large intestinal strangulating obstruction, enterocolitis, and
peritonitis. Logistic regression analysis revealed an association between the ET-like
immunoreactivity and outcome, whereas regression analysis revealed an association between
plasma ET-like immunoreactivity, PCV, and duration of signs of pain.
Two ET receptors have been identified and cloned: ETA receptors on the vascular
smooth muscle mediate vasoconstriction, and a subtype of the ETB (ETB2) receptors located
on the endothelium mediate vasodilatation via release of prostacyclin or NO (Clozel et al.,
1992). The expression of the ET family of vasoactive peptides increases in different tissues
such as intestine and heart of rats, humans, and dogs during low-flow ischemia, increased
shear stress, hypoxia, and inflammatory disorders (Rubanyi and Polokoff, 1994; Rubanyi
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Figure 3.3 - Logistic regression analysis showed a significant association between outcome
(survival vs non-survival) and plasma concentration of ET-like immunoreactivity (odds
ratio, 0.942; 95% CI, 0.890 to 0.998) and PCV (0.945, 0.896 to 0.996). Survival was best
explained by addition of both variables (ET-like immunoreactivity and PCV) to the logistic
model.
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and Vanhoutte, 1986). Endothelin-1 is believed to be the most important isoform, although
all isoforms have been identified in the intestine of people and mice (Inoue et al., 1989;
Saida, Mitsui, Ishida, 1989). Moreover, there is a growing body of evidence that ET-1 serves
as a principal mediator in pathophysiological events involving ischemia-reperfusion (I-R)
injury associated with intestinal strangulation obstruction and myocardial infarction in pigs
and human patients (Battistini and Dussault, 1998; Fevang et al., 1998). Because of the
reported cross-reactivity of the anti-ET-1 antibody used in the radioimmuonoassay with ET2 and ET-3, we could not specifically determine which ET isoform was present in the plasma
samples collected from affected and control horses. However, we presumed that the
immunoreactivity detected was primarily attributable to ET-1 because this is not only the
predominant isoform in the intestine of many animal species but it is also the circulating
isoform found during various pathologic conditions in several species (Fevang et al, 1998;
Weitzberg et al., 1991).
Because of its high metabolic activity and substantial blood flow requirements, the
gastrointestinal mucosa is the primary target tissue of many types of low-flow induced
circulatory shock associated with intestinal obstruction, hemorrhage and sepsis (Fevang et al,
1998; Weitzberg et al., 1991; Massberg et al., 1998) Occlusive vascular diseases and nonocclusive states associated with I-R lead to endothelial synthesis of ET (Rubanyi and
Polokoff, 1994). Increased intestinal vascular resistance during circulatory shock shunts
blood away from gastrointestinal tissues to more vital organs (Patel, Kaleya, Sammartaon,
1992), resulting in intestinal hypoperfusion. Increased plasma concentrations of ET-1 in pigs
with an intestinal strangulation obstruction may be associated with reduced intestinal blood
flow, intestinal hypoperfusion, and shock (Fevang et al., 1998). Nitric oxide, an endothelium73

derived vasorelaxant, inhibits the reduction ET synthesis (Boulanger and Luscher, 1990).
Further, during I-R injury and other low-flow states, endothelial production of NO is
compromised and responsiveness to ET-1 is enhanced (Thompson, Valeri, Lieberthal, 1995;
Wood et al., 1995). Thus, disruption of the balance between ET-1 and NO may lead to
prolonged vasoconstriction, resulting in impaired intestinal blood flow, ischemic injury and
ultimately mucosal barrier disruption.
Greater than 80% of the ET-1 synthesized by the endothelium is secreted
abluminally toward the tunica media where it functions in a paracrine fashion (Wagner et al.,
1992). Therefore, measurement of plasma ET-1 concentrations may not truly reflect the
overall synthesis and release of ET-1 during pathophysiologic events. Despite these
limitations, measurement of plasma ET-1 concentrations reportedly is a useful indicator of
congestive heart failure, pulmonary hypertension and endotoxemia in humans and other
animals (Nakamura et al., 1991; Lerman et al., 1991; Cody et al., 1992). The increase in
plasma concentrations of ET-like immunoreactivity that we detected in horses with
gastrointestinal tract disorders supports similar findings in pigs with strangulation
obstruction (Fevang et al., 1998). In addition, ET-1 mRNA expression was shown to be
increased in the small intestine of rats with peritonitis (Chou et al., 1995). Although we
detected significantly more plasma ET-like immunoreactivity in horses with gastrointestinal
tract disorders, compared with healthy horses, we could not determine whether this increase
was reflected solely by an increase in ET-1 or whether this increase was specific to horses
with colic. The increase in circulating ET-like immunoreactivity could have been attributable
to other factors related or unrelated to the primary disease.
The increase in plasma concentration of ET-like immunoreactivity that we detected
74

in affected horses may have resulted from specific stimuli leading to increased synthesis and
release of ET-1 from the vasculature of the affected intestinal segment or from the affected
gastrointestinal tract tissues. Shock-related stimuli may have also induced an increase in ET1 synthesis from tissues distant to the gastrointestinal tract. Alternatively, an increase in
concentration of circulating ET-1 may have simply resulted from hemoconcentration.
Lipopolysaccharides, tumor necrosis factor (TNF), and interleukin-1 (IL-1) are principal
mediators of sepsis and are also important modulators of ET-1 secretion (Battistini, Forget,
Laight, 1996; Dinarello, 1991). These and other regulatory peptides may activate the ET-1
gene through an acute phase response element of an upstream regulatory element (Marsden
and Brenner, 1992). In vitro ET-1 synthesis increases in cultured porcine aortic endothelial
cells stimulated with TNF and IL-1 (Kanse et al., 1991; Yoshizumi et al., 1990). Although
speculative, increased plasma concentrations of ET-like immunoreactivity that we detected
in affected horses may have resulted from endothelial injury or colic-associated stimuli
(interleukins or TNF) that lead to an increased release of ET-1 from the intestinal vascular
endothelium and subsequent spillover into the systemic circulation. However, the exact
mechanism for the increase in plasma ET-like immunoreactivity in horses with
gastrointestinal tract disorders could not be determined.
Median plasma concentration of ET-like immunoreactivity in horses was greatest in
horses with large intestinal strangulation obstructions, enterocolitis, and peritonitis.
Clinically, the magnitude of tissue damage and severity of shock are typically more severe in
horses with these conditions, compared with other causes of colic. In horses with obstructive
pulmonary disease, bronchoalveolar lavage fluid ET-1 concentrations were strongly
correlated with the severity of disease (Benamou et al., 1998). Thus, the high plasma
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concentrations of ET-like immunoreactivity in horses with the large-intestinal strangulating
obstruction, enterocolitis, and peritonitis, may also correlate with the severity of endothelial
damage and tissue injury, and may indicate involvement of ET-1 in the etiopathogenesis of
these disorders. Alternatively, high ET-like immunoreactivity concentrations may have
simply reflect a more severe systemic illness in these horses. In rats, administration of ET-1
leads to hemoconcentration, edema, and enhanced protein extravasations in various organs
including the duodenum (Valentin et al., 1991). In our study, the significant association
between plasma ET-like immunoreactivity concentration and PCV and the duration of signs
of pain may have been attributable to severe and long-standing disease that resulted in a
greater synthesis and release of ET-1. However, the increase in plasma ET-like
immunoreactivity concentration may also have been associated with the degree of
dehydration and altered cardiovascular status of the horses with severe gastrointestinal tract
disease.
Circulating concentrations of ET-1 associated with pathologic conditions can
affect systemic hemodynamics, resulting in increased systemic vascular resistance and
decreased cardiac output (Lerman et al., 1991). Logistic regression analyses revealed a
strong positive correlation between the plasma ET-like immunoreactivity concentration
and outcome (survival vs nonsurvival) in the horses of the present study. Similarly, in
humans with congestive heart failure, plasma ET concentrations are positively correlated
with the extent of pulmonary hypertension (Cody et al., 1992). However, from the present
study, we cannot determine whether the increase in plasma concentration of ET-like
immunoreactivity simply represents a biological marker for the disease severity, and
potentially, prognosis for horses with gastrointestinal tract disorders, or whether it
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contributes to the etiopathogenesis of these disorders. The use of ET-1 receptor
antagonists may help clarify the role of ET-1 as a biological marker or pathologic
mediator of colic in horses.
3.5 Product Information
a,b
c

Sigma Chemical Co, St Louis, Mo.

Endothelin, Nichols Institute Diagnostics, San Juan Capistrano, Calif.

d

Sep-Pak C18 columns, Waters Associates, Milford, Mass.

e

SAS for windows 95, version 7.0, SAS Systems Inc, Cary, NC.
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CHAPTER 4
DISTRIBUTION OF ENDOTHELIN-1 IMMUNOHISTOCHEMICAL STAINING
IN THE INTESTINAL TRACT OF CLINICALLY HEALTHY HORSES AND IN
THOSE WITH SMALL INTESTINAL AND LARGE COLON STRANGULATION
OBSTRUCTION
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4.1 Introduction
The gastrointestinal tract is the major target tissue of low-flow induced circulatory
shock such as occlusion, volvulus, hemorrhage and or sepsis (Alexander et al., 1990;
Massberg et al., 1995). Small intestinal and large colon strangulating obstruction account
for approximately 10% off all horses with colic, and these conditions are universally fatal
without surgical correction (Phillips and Walmsley, 1993). Despite surgical correction
and intensive medical care, most horses die due to the rapidity with which the intestinal
mucosa undergoes irreversible damage during ischemia, and subsequent endotoxemia and
hypovolemic shock. Increased plasma levels of endothelin-1 (ET-1) have been shown
during low-flow ischemia of the small intestine in various species like humans, pigs and
horses (Sharefkin et al., 1991; Fevang et al., 1998; Ramaswamy et al., 2002), suggesting
involvement of ET-1 in regulation of mucosal hypoperfusion and in the pathogenesis of
intestinal ischemia.
Endothelins are a family of vasoconstrictor peptides synthesized by various cells
that exert numerous biological and pathophysiologic actions via binding to G-linked
protein receptor subtypes, ETA and ETB (Yanagisawa et al., 1998; Rubanyi and Polokoff,
1994). All three ET isoforms (ET-1, ET-2 and ET-3) have 21 amino acids and 2 disulfide
bridges, each with different affinities for the ET receptors (Inoue et al., 1989). Each ET
isoform is a product of separate genes that encode the large precursor prepro-ET. Of all
ET isoforms present in the intestine (Matsumoto et al., 1989; Chou et al., 1995; de la
Monte et al., 1995), ET-1 is suggested as the most important isoform in the regulation of
intestinal functions.
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Endothelin-like immunoreactivity has been observed in endothelial cells, vascular
smooth muscle cells, mast cells, epithelial cells and various other cell types in the
intestinal tract of different species (Eaker et al., 1995; Liu, Yamada, Ochi, 1998;
Minchenko et al., 1999). In the human colon, ET and its binding sites were observed in
the enteric neurons, submucosal plexus, mucosal layer and in blood vessel walls (Inagaki
et al., 1991; Egidy et al., 2000). Expression of ET in vascular and non-vascular cells and
tissues suggests its diverse role in various physiological functions such as vasomotor
tone, ion secretion and closure of the ductus arteriosus (Coceani and Kelsey, 2000; Levin,
1995; Rubanyi and Polokoff, 1994). However, to our knowledge there are no studies
reported regarding the distribution of ET-1 in the gastrointestinal tract of horses.
Increased expression of ET-1 and intensity of staining in epithelial and
endothelial cells of the rat colon were correlated with the degree of mucosal injury
(Sugimachi et al., 2000). Hypoxia has been shown to induce an increase in ET-1 like
immunoreactivity in large intestinal endothelial and epithelial cells of rats (Dikranian et
al., 1994). It has been hypothesized that a sustained reduction in intestinal blood flow and
progressive mucosal injury after intestinal arteriovenous occlusion in horses could be
mediated principally by increased local expression and synthesis of ET-1 in the intestinal
microvasculature and tissues.
We hypothesized that there would be ET-1 staining in the surface epithelium and
vasculature of the gastrointestinal tract of normal horses, and this immunohistochemical
staining would increase in horses with naturally acquired intestinal strangulation
obstruction. The presence of ET-1 like immunoreactivity in the normal horse will suggest
its role in normal physiological functions, whereas increased expression of ET-1 in blood
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vessels and intestinal tissues during strangulation obstruction may indicate its
involvement in the pathogenesis of these disorders. The objectives of the study were to
evaluate the regional distribution of ET-1 in different segments of the gastrointestinal
tract of clinically healthy horses, and to determine and compare the expression of ET-1
like immunoreactivity in the intestinal segments of horses with naturally acquired small
intestinal and large colon strangulating obstruction.
4.2 Materials and Methods
4.2.1 Tissue Collection
This study was approved by the Clinical Animal Care and Use Committee of
Louisiana State University. Gastrointestinal tract biopsy specimens were collected from 6
clinically healthy adult horses with no history or clinical or laboratory evidence of
disease involving the gastrointestinal tract or cardiovascular system (control, n =6)
destined for euthanasia for other reasons. Samples were collected from the control horses
immediately after euthanasia with an overdose of pentobarbitala (100 mg/kg).
Sections were collected from the following sites from the gastrointestinal tract of
control horses: greater curvature of stomach, duodenum (1 foot from pylorus), ileum (1
foot from ileocecal junction), cecal body (half way between apex and base), right ventral
colon (1 foot from the cecocolic junction), left ventral colon (1 foot from pelvic flexure),
left dorsal colon (1 foot from pelvic flexure), right dorsal colon (1 foot from
diaphragmatic flexure), transverse colon (6 inches from duodenocolic ligament), and the
small colon (4 feet from duodenocolic ligament). All biopsy specimens were collected
from the anti-mesenteric side of the intestinal segments from control and affected horses.
Biopsy specimens were also collected from horses admitted to the LSU Veterinary
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Teaching Hospital with naturally acquired small intestinal (n=25) and large colon (n=13)
strangulation obstruction at the time of exploratory surgery or after euthanasia. Tissues
were fixed in 4% aqueous zinc buffered formalin for approximately 24 hours and
embedded in paraffin for immunohistochemistry.
4.2.2 ET-1 Immunohistochemistry
Paraffin-embedded tissues were serially sectioned at 4µm and attached to
silanized slides and dried overnight (37ºC). Tissues sections were deparaffinized,
hydrated through graded alcohol solutions, and equilibrated in phosphate buffered saline
(PBS, pH 7.6). Immunostaining was performed, using a modified three-step AvidinBiotin complex (ABC) method with a Vector Elite ABC Rabbit IgG kit (Hsu, Raine
Fanger, 1981). The entire staining procedure was performed at room temperature (2022ºC).
After rehydration, slides were immersed in 0.3% hydrogen peroxide in methanol
for 30 minutes to block endogenous peroxidase activity. Slides were rinsed and preincubated with normal goat serumb (1:50) for 45 minutes to block non-specific binding.
After incubation, the excess serum was removed and the primary antibody (Ab), rabbitanti-ET-1 antiserac at a dilution of 1:700, was added and incubated at room temperature
for 60 minutes. After addition of primary Ab, the slides were washed and incubated with
secondary biotinylated goat anti-rabbit-IgG antisera (1:200) for 30 minutes. The ABC
mixtured was applied for 30 minutes. The horse-radish-peroxidase substrates were then
developed by staining with freshly prepared chromogen, diaminobenzidine (DAB), for 5
minutes. The slides were counterstained with Mayer’s heamatoxylin for 30 sec,
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dehydrated with ethanol and xylene, cleared and mounted in a resinous media and
evaluated by light microscopy. Brown staining was considered positive.
The specificity for ET-1 like immunoreactivity was evaluated: 1) by the omission
of primary antibody; 2) by the substitution of normal rabbit IgG for primary antibody;
and 3) by pre-incubation of the primary antibody overnight at room temperature with
excess ET-1e peptide. The blocked antibodies were then used on tissue sections and run
parallel with immunostaining.
Three sections from each slide were evaluated twice to minimize variation. A
numerical value ranging from 0 to 3 was assigned to each slide based on the relative
amount of staining, with control slides (blocked control). The intensity and distribution of
the ET-1 like immunoreactivity for the following variables was evaluated: surface
epithelium, crypt epithelium, mucosal vasculature, submucosal arterioles and venules
(smooth muscle, endothelium), muscularis and serosa. A zero score was assigned if there
was no staining present. Grade 1 - indicated a mild increase brown staining compared
with blocked antibody; Grade 2 - indicated a moderate increase brown staining compared
with blocked antibody; and Grade 3 - indicated an intense increase in brown staining over
that with blocked antibody.
The affected segments (duodenum, jejunum, ileum, pelvic flexure) of horses
with small intestinal and large colon strangulating obstruction were compared with the
duodenum, jejunum, ileum, and pelvic flexure scores from control horses. The modal
(most frequent) scores were reported as a summary measurement for each tissue, stain,
and variable.
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4.3 Results
In healthy horses, the intestinal surface epithelium and large vessels, mainly the
veins and the muscular layer, were positive for ET-like immunoreactivity (Figures 4.1,
4.3 and 4.4). No staining was observed in mucosal mucus glands, and Brunner’s glands in
duodenum and jejunum, respectively (Figure 4.2). The observed ET-like
immunoreactivity was completely abolished by pre-absorption of antiserum with an
excess amount of ET-1 (Figure 4.1B and 4.3B). Under high magnification, ET-like
immunoreactivity was observed in the cytoplasm of the surface epithelial cells and
endothelial cells with moderate staining intensity. The staining was more intense in the
apical region of the surface epithelium. The surface epithelial cells also showed a mosaic
distribution pattern of ET-like immunoreactivity (Figure 4.4). Staining of crypt
epithelium and endothelial cells were variable and inconsistent. Veins stained more
intensely than arteries (Fig 4.5). ET-like immunoreactivity was diffuse and variable in the
endothelium of the blood vessels. The ET-like immunoreactivity staining in muscularis
was diffuse and variable, with greatest intensity of staining observed in the outer
muscular and serosal layers.
Heavy hemorrhage, congestion and lack of structural details in affected tissue
segments from horses with naturally acquired intestinal strangulation obstruction made it
difficult to subjectively evaluate ET-like immunoreactivity. Overall, staining intensity
was greater in the serosal and outer muscular layers of the affected intestinal segments
(Figure 4.6). Diffuse staining was also noted in the mucosa and in blood vessels of
affected intestinal segments. The staining was intense and diffusely distributed in affected
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A

B

Figure 4.1 Photomicrograph showing ET-like immunoreactivity staining in the surface
epithelium of the duodenum of a clinically healthy normal horse (A). The ET-1
immunoreactivity was abolished by pre-absorption of anti ET-1 with excess amount of
ET-1 (B).
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Figure 4.2 Photomicrograph illustrating the lack of ET-like immunoreactivity in the
mucus of the duodenal glands (↑).
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B

A

Figure 4.3 Photomicrograph illustrating intense ET-like immunoreactivity in the surface
epithelium and lamina propria of the ileum of a clinically healthy horse (A). Preabsorption of anti-ET-1 antibody with ET-1 abolished the ET-like immunoreactivity (B)
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Figure 4.4 Photomicrograph illustrating patchy distribution of ET-like immunoreactivity
(arrow heads) with anti-ET-1 Ab staining in the pelvic flexure of clinically healthy horses
(A). Note the intense staining in the blood vessels (↑) in the lamina propria.
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A

B
Figure 4.5 Photomicrograph illustrating intense ET-like immunoreactivity in the tunica
media and endothelial lining of the blood vessels in a healthy horse (A) and in horse with
large colon strangulation obstruction. B) ↑- indicate the endothelial lining of blood
vessels.
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Figure 4.6 Photomicrograph illustrating diffuse and intense ET-like immunoreactivity in
the muscular and serosal layer of pelvic flexure of horse with colon torsion. Note the
intense staining in the endothelial lining of the blood vessels (↑).
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Figure 4.7 Photomicrograph illustrating diffuse ET-like immunoreactivity in the mucosal
layer, due to extensive mucosal damage in the pelvic flexure of horse with colon torsion.
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intestinal segments from horses with large colon volvulus, compared with control tissues
(Figure 4.7). The modal scores for clinically healthy horses varied from 0 and 1
depending on tissue type and variable (Table 4.1). Overall, the modal (most frequent)
scores of ET-1 staining intensities were higher (2) compared with the ET-1
immunoreactivity staining in clinically healthy horses (Table 4.2)
4.4 Discussion
The distribution of ET-like immunoreactivity was examined in the gastrointestinal
tract of healthy horses and in intestinal segments from horses with naturally acquired
intestinal strangulation obstruction. The most important findings of this study were the
presence of ET-1 like immunoreactivity in the villi and surface epithelium of the small
intestine and large intestine, respectively, in healthy horses. This suggests a role for ET-1
on normal gastrointestinal tract function. The ET-like immunoreactivity was
predominantly confined to the cytoplasm of the surface epithelium with less staining in
the crypts, and variable, diffuse ET-like staining in the muscularis layer. A similar pattern
of ET-immunoreactivity has been reported in rat colon (Sugimachi et al., 2000). The
endothelial lining of blood vessels in different segments of the gastrointestinal tract
stained positive for ET-1, suggesting its involvement in the regulation of regional
intestinal blood flow.
Localization of ET-1 was investigated using apolyclonal antibody against ET-1
(rabbit). Due to the cross reactivity of anti-ET-1 antibody used in the study (ET-1-100%;
ET-2 - 91%; ET-3-0.05%), we could not specifically determine the ET isoforms present
in the gastrointestinal tract. However, it is mostly ET-1 because of its predominant
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Table 4.1 Modal values for ET-1 immunoreactivity staining scores in different sections
and tissue types of the gastrointestinal tract of clinically healthy horses
Epithelium
Tissue Sites
Duodenum (n =5)
Jejunum (n =5)
Ileum(n =6)
Cecum (n =6)
Pelvic flexure(n =4)
Right ventral colon(n =6)
Right dorsal colon (n =5)
Left ventral colon (n =6)
Left dorsal colon (n =6)
Small colon (n =6)
Transverse colon (n=6)

B.V
Surface Crypt
2
0
1
0
1
0
2
0
1
0
0
0
1
0
1
0
1
1
1
0
1
0

0
0
0
1
1
0
0
0
1
0
0

T.media

Endothelium

1
1
1
2
1
0
0
1
1
1
0

0
0
1
0
1
0
1
1
0
0
0

SM
1
1
1
1
1
1
1
1
1
1
1

B.V – blood vessels, T. Media – tunica media, SM – smooth muscle

Table 4.2 Modal values of ET-1 immunoreactivity staining scores in affected intestinal
segments from horses with naturally acquired small intestinal and large colon
strangulation obstruction.
Tissues

Epithelium

SI strangulation (n =25)

2

Artery
(M)
2

LI strangulation (n =13)

2

1

Blood Vessels
Vein
Endothelium
(M)
2
2
2

SI- small intestinal, LI- large intestinal, M- muscle, SM-smooth muscle
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1

SM
2
2

distribution in the intestinal tract and the fact that ET-like immunoreactivity was
abolished by pre-absorption of anti-ET-1 with excess amount of ET-1. Endothelins, 21
amino acid peptides, are present in nearly every organ examined. Of the three isoforms,
ET-1 and ET-2 were expressed in the gastrointestinal tract (de La Monte et al., 1995);
and are potent constrictors of intestinal smooth muscle. The ET receptor types (ETA and
ETB) have been identified in the intestine of pigs, humans and other species and have
been found to have increased expression in young animals (Nankervis, Dunaway, Miller,
2001; Egidy et al., 2000). The roles of ET-1 in the regulation of intestinal hemodynamics
and oxygenation of tissues have been studied (Nankervis, Dunaway, Miller, 2001). The
presence and identification of ET-1, and its receptor types in the intestinal tissues suggest
a physiological role of ET-1 in intestinal function.
The release of ET-1 occurs in discontinuous pulses from the blood vessels and
helps in maintenance of vasomotor tone. The inconsistent ET-1 staining of endothelial
cells within different sections of the intestine may thus reflect the state/change in ET-1
production by the blood vessels. Similar variable staining intensity and the diffuse nature
of ET-1 staining was observed in previous studies in rat colon (Sugimachi et al., 2000)
and human placenta (Barros et al., 2001).
The ET-1 immunolabelling was identified as single particles in normoxic rat large
intestine, but only in low levels with labeling predominantly confined to the cytoplasm of
endothelial cells of mucosal arterioles and post-capillary venules (Dikranian et al., 1994).
The expression of ET-1 like immunoreactivity in the intestinal surface epithelium of the
horses in this study suggests that ET-1 might play a role in epithelial cell differentiation
or secretory activity as suggested by others in different species (Takahashi et al., 1990; de
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la Monte et al., 1995; Shichiri, Marumo, Yukio, 1998). The gastrointestinal tract
epithelial cells and intestinal vasculature possess ETA and ETB receptors (Inagaki et al.,
1991; Nankervis, Dunaway, Miller, 2001). Therefore, the observed ET-1 like
immunoreactivity in the villi and surface epithelial cells may reflect a paracrine type of
uptake of ET secreted by endothelial or lamina proprial cells.
During shock or low-flow states, ET-1 release likely plays a role in helping to
shunt blood away from the splanchnic circulation to more vital organs (Fevang et al.,
1998). Although this is a needed defense mechanism, it likely contributes to the
continued ischemia in the post-operative period, or subsequent to shock resuscitation, and
could result in mucosal barrier disruption. Further, the functional role of ET-1 in
gastrointestinal functions like intestinal motility and ion secretion has been elucidated
(Moummi et al., 1992; Hosokawa et al., 1995). Recently, we reported an increase in
plasma ET-like immunoreactivity in horses with acquired gastrointestinal tract disorders
such as large intestinal strangulation obstruction, peritonitis and enterocolitis
(Ramaswamy et al., 2002). The mechanism of increased plasma ET-1 concentrations in
various gastrointestinal tract disorders (Murch et al., 1992; Ramaswamy et al., 2002)
though unclear, is speculated to be an increased synthesis or release of ET-1 by injured or
stimulated endothelial cells from affected intestinal tissues and subsequent absorption
into the circulation, rather than the systemic release of ET-1 from other tissues.
Submucosal injection of ET-1 induces gastric ulceration secondary to a decrease in
gastric mucosal blood flow, ischemia and increased acid secretion (Watanabe et al.,
2000).
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In our study, increased intensity of ET-like immunoreactivity in the outer
muscular layer and blood vessels of the intestinal segments collected from horses with
acquired intestinal strangulating obstruction disorders was observed. The increased
expression of ET-1 may enhance epithelial damage because of its ability to cause
vascular contraction and ischemia. However, the lack of structural details due to
advanced disease conditions and variable staining intensity between viable and nonviable sections of affected tissues makes it difficult to confirm this assumption.
Involvement of ET-1 in the pathogenesis of various intestinal disorders has been
previously indicated by immunohistochemistry (Chou et al., 2001; Sugimachi et al.,
2000). Similarly, increased ET-1 staining in various cancer cell lines, in human patients
with prostate cancer and pituitary adenoma, and in ischemic rat colon tissues, compared
with control tissues, has been reported (Sugimachi et al., 2000; Asham et al., 2001; de
Matteis et al., 2001). Investigating the role of ET-1 in intestinal disorders using ET
antagonists could further extend the clinical implications of this study.
In conclusion, this study demonstrated the presence and distribution of ET-1 in
the intestinal tract of normal horses suggesting its role in physiologic functions. The
increased expression of ET-1 observed in affected intestinal segments supports the
hypothesis that ET-1 is involved in the pathogenesis of ischemic injury in horses.
4.5 Product Information
a

Beuthanasia-D®, Schering-Plough Animal Health, New Jersey.

b

Normal Goat serum, Vector Laboratories, Burlingame, Calif.

c

Rabbit-anti endothelin, Peninsula Laboratories, Belmont, Calif.

d

Vectastain, Elite ABC Kit, Vector Laboratories, Burlingame, Calif.

98

e

Endothelin-1, Sigma-Aldrich Co, St. Louis, Mo.
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CHAPTER 5
DETECTION OF ENDOTHELIN-1 GENE EXPRESSION IN THE
GASTROINTESTINAL TRACT OF CLINICALLY HEALTHY HORSES USING
POLYMERASE CHAIN REACTION
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5.1 Introduction
Endothelins (ET), a family of highly conserved 21 amino acid peptides, possesses
potent vasoconstrictor activity and numerous other functions in mammals (Rubanyi and
Polokoff, 1994). They were originally isolated from cultured porcine endothelial cells
(Yanagisawa et al., 1988) and later expressed in other cell types in the nervous, urinary,
respiratory and gastrointestinal systems (Rubanyi and Polokoff, 1994; Inagaki et al.,
1991). Three different isoforms of ET, including ET-1, ET-2 and ET-3, each encoded by
a separate gene, have been identified in humans and other species (Inagaki et al., 1991;
Inoue et al., 1989; Shiba et al., 1992). Endothelin isoforms are processed as large preproforms and post-translationally processed to active peptides. Endothelin synthesis is
regulated by various stimuli (hypoxia, hormones, cytokines) at the transcriptional level
(Shiba et al., 1992; Levin, 1995; Elton et al., 1992; Yoshizumi et al., 1990). Endothelins
exert their pharmacological action by binding to two distinct high affinity receptors
subtypes, ETA and ETB, which are seven-transmembrane G-protein-coupled receptors
(Inagaki et al., 1991) distributed widely in a variety of cell types including vascular
smooth muscle, endothelial cells and macrophages.
Endothelins are widely expressed in various mammalian tissues and organs
including the gastrointestinal tract, and localization of ET receptors in the intestinal tract
of bovine, rats, and other laboratory animal species has been documented (Inagaki et al.,
1991). These isopeptides have a variety of biological roles, including involvement in
vasoconstriction, cell growth, and intestinal and bronchial smooth muscle contraction
(Levin, 1995; Elton et al., 1992; Yoshizumi et al., 1990). Several inflammatory mediators
such as vasopressin, angiotensin, lipopolysaccharide, tumor necrosis factor-α and
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interleukins stimulate the synthesis of ET. Endothelin synthesis is also enhanced by a
variety of other stimuli such as low shear stress and hypoxia (Levin, 1995; Elton et al.,
1992). Several studies have emphasized the gastrointestinal tract as a major target of the
endothelins (Chou et al., 1995). High concentrations of plasma ET-1 have been observed
in various pathological conditions such as sepsis, ulcerative colitis, Crohn’s disease and
endotoxemia (Murch et al., 1992; Myhre et al., 1993). Recently, we observed increased
circulating plasma ET-like immunoreactivity in horses with naturally acquired
gastrointestinal tract disorders such as strangulation obstruction, enterocolitis and
peritonitis (Ramaswamy et al., 2002). To our knowledge, no studies have reported ET-1
gene expression in the gastrointestinal tract of horses. The expression and relative
amounts of ET-1 gene expression in gastrointestinal segments should enable us to further
determine the physiological and pathological role of ET-1 in the gastrointestinal tract in
horses.
We hypothesized that the ET-1 would be found in variable quantities from various
segments of the intestinal tract extending from the duodenum to the right dorsal colon of
healthy horses. The primary objective of the study reported here was to determine the
presence of the equine ET-1 gene expression in different sections of the gastrointestinal
tract of clinically healthy horses, using reverse-transcriptase polymerase chain reaction.
5.2 Materials and Methods
This study was approved by the Institutional Animal Care and Use Committee of
Louisiana State University. Tissue samples from 6 clinically healthy horses donated for
reasons unrelated to gastrointestinal tract disorders were obtained immediately after
euthanasia with intravenous sodium pentobarbitala (100 mg/kg, IV). Samples were
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collected from various sections of the gastrointestinal tract extending from the stomach to
the large colon. For uniformity in tissue collection, the following landmarks were used:
stomach (halfway around the greater curvature), duodenum (1 foot from pylorus),
jejunum (25 foot from ileocecal junction), ileum (1 foot from the ileocecal junction),
right dorsal colon (1 foot orad to diaphragmatic flexure), pelvic flexure and right ventral
colon (1 foot from cecocolic orifice). A section of heart (left ventricular wall) tissues
were also collected. Full-thickness tissue samples were collected, immediately snap
frozen in liquid nitrogen and stored at –80°C until analyzed.
Total RNA was extracted using TRI REAGENT LS according to the
manufacturer’s instructionsb. The RNA samples were heat inactivated at 65°C for 10min
and chilled on ice 2 min. The RNA samples were reverse-transcribed by adding 25 µL of
DEPC treated water, 1 µL of oligo(dT) primers and Ready-To-GOTM You-Prime FirstStrand Beadsc.
Oligonucleotide primer pairs specific for the equine ET-1 gened were designed
and synthesized in our laboratorye. The ET-1 gene was then amplified from the cDNA by
use of primers specific for equine ET-1, 5´-AAGCAGGAAAAGAACTCAGGTGAG-3´
(FP) and 5´-CAGCCTTTCTCCATAGTGTCTTGG-3´ (RP). The ET-1 amplification
product was predicted to be 202 bp in length. The PCR reaction mixture consisted of 3
µL of cDNA, 1 µL of forward and reverse primers (20 µM), 10 µL of PCR buffer, 10 µL
of dNTP, 0.5 µL of Taq polymerase, and a sufficient amount of distilled water to have a
final volume of 100 µL. The PCR reactions were performed in a thermal cycler
programmed as follows: initial denaturation at 96°C for 3 min; cDNA was amplified in
35 cycles (94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec). Subsequently, final
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extension was performed at 72°C for 10 min. A negative control (no template) was run to
avoid any false positive reactions from exogenous contaminating DNA. The gels were
visualized with an ultraviolet transilluminator and the gels were photographed with a
Fluor-STM Multi-imager.
5.3 Results
We confirmed the identity of the PCR products by sequencing after extensive
purification, using an automated DNA sequencerf. The resultant sequences were
confirmed by comparison to the known published partial sequence of equine ET-1d.
Agarose gel electrophoresis of PCR products from the various sections of the
gastrointestinal tract tissues, including the stomach, duodenum, jejunum, ileum, right
ventral colon, pelvic flexure and right dorsal colon, demonstrated the expected product
sizes, (Figure 5.1) and are identical to the published nucleotide partial sequence. No
amplification signal was noticed in the negative control samples.
5.4 Discussion
To our knowledge, this is the first study to demonstrate the presence of
constitutively expressed of equine ET-1 gene in various sections of the gastrointestinal
tract of horses. Although this study showed the presence of the ET-1 gene expression in
the gastrointestinal tract of clinically healthy horses, it does not reveal any information
regarding the cellular localization or differential expression of ET-1 within the
gastrointestinal tract tissues or alterations with disease conditions. Endothelins are
multifunctional, vasoconstricting peptides exhibiting vasoactive, inotropic, and mitogenic
properties, and have the ability to modulate other hormone systems as well as intestinal,
renal and pulmonary function (Rubanyi and Polokoff, 1994; Inagaki et al., 1991; Inoue et
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Figure 5.1 - Agarose gel (1.5 %) electrophoresis pattern of RT-PCR amplification
products of equine ET-1 in tissues collected from different sections of gastrointestinal
tract tissues of clinically healthy horses. Lane 1- stomach, Lane 2- duodenum, Lane 3jejunum, Lane 4- ileum, Lane 5- right ventral colon, Lane 6- Marker (100bp), Lane 7pelvic flexure, Lane 8- right dorsal colon, Lane 9-Lung, and Lane 10-heart.
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al., 1989; Shiba et al., 1992). Induction of ET-1 synthesis is controlled at the level of
transcription of its precursor, preproendothelin-1. Therefore, the presence of ET-1 gene
should directly reflect the relative amount of ET-1 peptide based on the assumption that
there is no posttranscriptional regulation of ET-1. Endothelin isoforms are initially
synthesized as large precursor polypeptides, pre-proET, that are cleaved at two pairs of
basic amino acids to generate intermediate peptides, big ET-1. The big ET-1 is posttranslationally processed to active peptide, ET-1, by endothelin converting enzyme (ECE)
present in the cell surface (Rubanyi and Polokoff, 1994). A number of studies on the
distribution of the ET-1 mRNA in a variety of tissues such as stomach have been reported
(Egidy et al., 2000; Guan, Chen and Qian, 1998). Expression of ET-1 mRNA has been
reported in wide variety of cell types such as macrophages, vascular smooth muscle cells,
myocytes, astrocytes and mast cells (Liu, Yamada, Ochi, 1998; Dikranian et al., 1994).
The ET-1 and ET-3 peptides were shown to be present in the gastrointestinal tract of
other species; they have been identified in rat gut mucosa by radioimmunoassay and by in
situ hybridization (Takahashi et al., 1990, MacCumber et al., 1989).
Studies have shown the presence of ET-1 mRNA expression in a variety of tissues
such as lung, uterus, ovary, stomach and intestinal tissues of rats (Takahashi et al., 1990).
In rat large intestine, ET-1 has been identified in the lamina propria as single particles
suggesting that this peptide has a role in villus motility (Dikranian et al., 1994). Studies
have found ET-like immunoreactivity, binding sites for ET-1 and the presence of ECE
mRNA in the human colon, and ET-1 seems to be a potent intestinal secretagogue that
increases colon contraction by direct stimulation of smooth muscle (Mac Cumber et al.,
1989). However, sites of ET-1 synthesis in the equine intestinal tract and its relation to
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physiological function (motility, secretion) and in pathological conditions such as
ischemia-reperfusion injury, inflammatory bowel disease or post-operative ileus have yet
to be determined.
The finding of ET-1 gene expression in different sections of the equine
gastrointestinal tract is of particular importance owing to the multifunctional role of ET-1
in the gastrointestinal tract of other species (Chou et al., 1995; Murch et al., 1992).
Additionally, involvement of ET-1 in a variety of gastrointestinal tract disorders such as
ischemia-reperfusion injury, inflammatory bowel disease, peritonitis, and paralytic ileus
has been suggested in various species (Egidy et al., 2000). In horses, studies have
implicated the role of ET-1 in the pathophysiology of chronic obstructive airway diseases
and laminitis (Benamou et al., 1998; Katwa et al., 1999). In our recent study, we found
increased plasma ET-like immunoreactivity in naturally acquired gastrointestinal
disorders, compared with clinically healthy horses; specifically horses with strangulation
obstruction, enterocolitis and peritonitis had the greatest concentrations, suggesting its
potential role in these disorders (Ramaswamy et al., 2002).
Identification of ET-mRNA in the gastrointestinal tract of healthy horses suggests
that intestinal segments may be a source of ET-1 production during gastrointestinal tract
disorders as observed in our previous study (Ramaswamy et al., 2002). The RT-PCR
conditions, including the optimization of primers used in this study, may be useful in
analyzing the relative levels of ET-1 gene expression in pathophysiological conditions of
horses using further quantitative or semi-quantitative PCR methods such as the
ribonuclease protection and TaqMan assays. Taken together with the fact that ET-1 has
specific receptors and pharmacological activities in these ET-1 producing tissues, our
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study suggests that ET-1 may play an important role as a locally (and perhaps
systemically) acting regulating/modifying physiological modulator and might be an
important pathological mediator.
In conclusion, the present study identified the presence of the ET-1 gene expression
in various sections of the gastrointestinal tract in healthy horses, suggesting a role of ET1 as a regulator of intestinal function. Studies showing the presence of ET-1 and the
correlation with other findings with various disease conditions make it important to
perform further studies such as in situ hybridization and quantitative studies (TaqMan
assay) to determine the distribution and differential expression of ET-1 throughout the
different segments of the gastrointestinal tract and within different components of the
intestinal wall of clinically healthy horses.
5.5 Product Information
a

Beuthanasia-D®, Schering-Plough Animal Health, NJ.

b

TRI REAGENT-LS®, Molecular Research Center Inc, Cincinnati, OH.

c

Ready-To-GOTM You-Prime First-Strand Beads, Amersham Pharmacia Biotech Inc,

Piscataway NJ.
d

GenBank Accession AF130760, National Center for Biotechnology Information

(NCBI) National Library of Medicine (NLM) at National Institute of Health (NIH),
Bethesda, Md.
e
f

Gene Lab, College of Veterinary Medicine, Louisiana State University, Baton Rouge

ABI PRISM 377 DNA sequencer, Perkin Elmer, Foster City, Calif.
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CHAPTER 6
CHARACTERIZATION OF ENDOTHELIN-1 MEDIATED IN VITRO
RESPONSES OF CECAL LONGITUDINAL SMOOTH MUSCLE IN HORSES
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6.1 Introduction
Endothelin-1 (ET-1), a 21 amino acid vasoconstrictor peptide, is expressed in a
variety of cell types including endothelial cells, mast cells, macrophages, mesangial cells,
and central and peripheral neurons (Takahashi et al., 1990; Rubanyi and Polokoff, 1994).
Endothelins have been suggested to play a broader role in diverse physiological functions
such as intestinal secretions, motility, maintenance of vasomotor tone, and closure of the
patent ductus arteriosus (Shahbazian and Holzer, 2000; Rubanyi and Polokoff, 1994;
Coceani, Kelsey, Seidlitz, 1992). Endothelin-1 exerts its biologic activity by binding to
its receptors, ETA and ETB. The ETA receptors are located on smooth muscle and mediate
contraction. On the other hand, the vascular ETB receptors, ETB2 are located on
endothelial cells and mediate relaxation by the release of nitric oxide (NO). The ETB
receptors, ETB1 on non-vascular smooth muscle mediate constriction (Clozel et al., 1992).
Actions of ET-1 in intestinal smooth muscle are complex, and involve both excitatory
and inhibitory effects depending on the type of receptor, section of tissue and species
involved (Takahashi et al., 1990; Bolger et al., 1990; Eglen et al., 1989). Most of the
actions of endothelins in the gastrointestinal tract are contractile and occur via their direct
actions on the smooth muscle (Okabe et al., 1995).
Gastrointestinal motility is regulated by the enteric nervous system together with
excitatory and inhibitory neurons of the nonadrenergic- noncholinergic (NANC) system
(Van Hoogmoed et al., 2000; Malone et al., 1999). Endothelins are shown to be localized
in the enteric nervous system (Takahashi et al., 1990; Inagaki et al., 1991) and have been
proposed to exert important modulatory actions on gastrointestinal motility (Takahashi et
al, 1990; Allcock et al., 1995; Miasiro et al., 1999). The involvement of ET-1 in intestinal
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motor regulation is due to the presence of both types of ET receptors, ETA and ETB, in the
gastrointestinal tract (Inagaki et al., 1991; Yoshinaga et al., 1992). Endothelin-1 caused
concentration-dependent contraction in isolated longitudinal smooth muscle of rat cecum
and in opossum internal anal sphincter smooth muscle (Okabe et al., 1995 Chakdar and
Rattan, 2001).
The role of NANC innervation in the gastrointestinal tract has been studied in a
variety of species, including rats, sheep, cats and horses (Venkova and Krier, 1994; Reid
and Titchen, 1988; Van Hoogmoed et al., 2000). Functions of the NANC inhibitory
components have been detected in jejunum and ventral colon of horses (Van Hoogmoed
et al., 2000; Malone et al., 1999). The role of nitric oxide (NO) and vasoactive intestinal
peptide (VIP) in inhibitory neurotransmission in the equine jejunum and ventral colon has
been reported using pharmacological agents (Van Hoogmoed et al., 2000; Rakestraw et
al., 1996). The NO released from NANC allows receptive relaxation aboral to bolus
during peristalsis. In horses, motility disorders are associated with a variety of pathologic
conditions, including impaction, postoperative ileus, endotoxemia, and peritonitis
(Blikslager et al., 1994; Alican et al., 1998). Luminal distention associated with
impaction, strangulation obstruction, and ischemic injury results in gastrointestinal
motility disturbances by interfering with the functions of various neurotransmitters such
as NO, acetylcholine (ACh), norepinephrine (NE) and VIP. No studies have been
reported regarding the role of ET-1 in the gastrointestinal tract of healthy horses. A study
on isolated cecal tissue will allow a more definitive evaluation of the presence of ET
receptors on cecal smooth muscle and its potential role in cecal motility.
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We hypothesized that ET-1 would cause concentration dependent contraction of
cecal longitudinal smooth muscle, mediated by ETA and ETB receptors. Also, we
hypothesized that ET-1 will cause contractions similar to those produced by carbachol in
equine longitudinal smooth muscle. The purposes of the study reported here was to
characterize the ET-1 mediated responses in isolated equine cecal longitudinal smooth
muscle and compare them with carbachol, a well-known intestinal smooth muscle
contractile agent. Additionally, the role of ETA and ETB receptors in the mediation of ET1 induced responses in equine cecal longitudinal smooth muscle was studied using
specific ET receptor antagonists.
6.2 Materials and Methods
6.2.1 Animals and Tissue Collection
The study was approved by the Louisiana State University Institutional Animal
Care and Use Committee. Tissues collected from adult healthy horses (n=36) that were
destined for euthanasia for reasons unrelated to any apparent gastrointestinal tract or
systemic diseases were used. Tissues were collected immediately after euthanasia with
an overdose of pentobarbital sodiuma (100 mg/kg, IV). A 15-cm long segment from the
cecal base along the ventral taenia was collected, ingesta were gently removed by lavage
with 0.9% NaCl and the tissue was placed in a beaker containing oxygenated, modified
Kreb’s solution. The tissue segments were pinned flat in a dissecting bath containing
sufficient warm (37˚C) oxygenated Kreb’s buffer solution to ensure that tissues were
completely immersed, and bubbled with a mixture of 95% O2 and 5% CO2. The intestinal
mucosa and submucosa were removed gently with sharp dissecting scissors and strips
measuring 2-mm wide and 10-mm long were cut parallel to the taenia to obtain
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longitudinal muscle sections and perpendicular to the taenia to obtain circular smooth
muscle strips. All samples were tested in duplicate.
6.2.2 Drugs and Reagents
All solutions were prepared on the day of the experiment. Endothelin-1b, ETA
receptor antagonist (BQ-123)c and ETB receptor antagonist (IRL-1038)d, carbachole,
atropinef, and guanethidineg and tetrodotoxinh were used. The drugs were dissolved
according to manufacturer’s instructions with distilled water. The ET-1 was reconstituted
in distilled water and stored in aliquots of 10-4M at –80˚C. Aliquots were thawed
immediately prior to use and further diluted to the desired concentration. Carbachol was
dissolved in distilled water immediately before use. The composition of modified Kreb’s
solution was as follows [mM]: NaCl, 118; MgSO4, 1.2; CaCl2, 2.5; KCl, 4.7; NaHCO3,
24.9; and dextrose [pH 7.3 to 7.4].
Preliminary studies (n=6) were conducted to determine the appropriate resting
tension and equilibration period for tissues to determine the effect of ET-1. Results from
our study showed that a resting tension of 2 g was required to elicit a consistent
contractile pattern, which is similar to previously reported studies (Van Hoogmoed et al.,
2000; Rakestraw et al., 1996; Malone et al., 1999). Both longitudinal and circular muscle
strips exhibited spontaneous contractile activity. The spontaneous activity of
longitudinally-oriented smooth muscle was cyclic and occurred at a steady rate of
approximately of 2-3 contractions per minute (25mm/min). The circular smooth muscle
occurred in a pattern typical to that of colonic tissue, however, the pattern of contractions
during the 3-minute period didn’t sufficient enough to evaluate the response of
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exogenous agents added. So further experiments were conducted on longitudinal smooth
muscle.
6.2.3 Experimental Protocol
One end of each strip was mounted to the floor of the organ bath (10 ml) and the
other end was attached to a force-displacement transduceri, interfaced with a polygraphj,
to record the change in tension. For evaluation of tissue responses, intestinal smooth
muscle tissues were equilibrated for 45-minutes in the organ baths containing Kreb’s
solution maintained at 37˚C by a circulating water and oxygenated with a gas mixture of
95% O2 and 5% CO2. Resting tension was set at 2 grams and tissues were allowed to
equilibrate for an additional 60 minutes. Throughout the experiment, Kreb’s solution was
changed at 15-minute intervals.
Based on preliminary studies, further experiments were performed to
characterize the role of ET-1 in the longitudinal smooth muscle. Tissues from 6 horses
(48 strips) were used for determining the concentration-response (C-R) relationships of
both ET-1 and carbachol and 18 horses (104 strips) were used for C-R relationships of
ET-1 in the presence of ETA and ETB receptor antagonists, separately and together.
6.2.3.1 Concentration-Response Relationships of Carbachol and ET-1 on Cecal
Longitudinal Smooth Muscle
After a 95-minute equilibration period, cumulative C-R relationships for ET-1 and
carbachol at graded concentrations of 10-9, 10-8, 10-7 and 10-6 M were performed in
separate baths. Each dose was added at 3-minute intervals and changes in tension were
recorded.
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6.2.3.2 Effect of ET Antagonists, BQ-123, IRL-1038, Separately and Together on
ET-1 Induced Response
After the application of 2 g tension, the tissues were incubated separately with
ETA (BQ-123) and ETB (IRL-1038) antagonists, at 3 concentrations of 10-9, 107 and 10-5
M, for a period of 45 minutes, and a C-R relationship of ET-1 (10-9 to 10-6M) was then
determined. Similarly, cecal muscle strips were incubated with 3 individual
concentrations of 10-9, 107 and 10-5M of the combined antagonists for a period of 45
minutes, and a C-R relationship of ET-1 (10-9 to 10-6M) was determined as before.
6.2.3.3 Electrical Field Stimulation (EFS)
The electrodes used for the EFS consisted of a pair of platinum wires fixed at both
sides of the smooth muscle strip. Electric field stimulation was generated by a stimulatork
and applied to all tissues simultaneously. Repetitive stimuli (trains) at 3-minute intervals
of millisecond duration pulses were tested at intensities of 40V and 60V, with frequency
of 5Hz, 10 Hz and 20Hz to the cecal longitudinal smooth muscle preparations. These
stimulation parameters have been shown to cause facilitate intestinal smooth muscle
responses in horses (Malone et al., 1999). In our study, tissues were given repetitive
stimuli at 3-minute trains of 10 millisecond duration pulses at intensities of 60V and
20Hz to the longitudinal smooth muscle preparation. Tissues from 5 horses were
prepared as before and allowed to equilibrate for 1 hr, after which a resting tension of 2 g
was set and EFS applied. In a separate set of experiments, after equilibration, tissues were
incubated with atropine (10-5M) and guanethidine (10-5M) for 45 minutes and EFS was
applied. Tetrodotoxin (10-3M), a sodium channel blocker, was added to test the role of
nerve conduction in the EFS induced contractions.
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6.3 Data analysis
The percentage changes in baseline tension were quantified by measuring
percentage change in the area under the curve (AUC) using Image Analysis Softwarel.
The active change in tissue responses was calculated as the percentage change from
baseline tension. The percentage change in baseline tension for ET-1 responses was
calculated by measuring the AUC 3-minutes prior to the addition of the drug compared
with the AUC during the 3-minute period after each dose was added (Rakestraw et al.,
1996). The changes in tension due to ET-1 were compared with carbachol and with and
without the ET receptor antagonists.
All data were considered continuous and followed a normal distribution as noted
by failure to reject the null hypothesis of normality at P <0.05, using the Shapiro-Wilk
test. The data were summarized as mean ± SEM and was evaluated for an effect of
antagonist and concentration, using a mixed linear model accounting for the random
variance of horse. Where there were significant interaction effects at P <0.05,
predetermined multiple comparisons were made across concentrations within each
antagonist group, and between groups at specified concentrations, using least squares
means maintaining type I error at 0.05. PROC UNIVARIATE and PROC MIXED were
used for the analysis using software.m
6.4 Results
Both longitudinal and circular smooth muscle showed spontaneous contractile
activity (Figure 6.1). The addition of ET-1 produced a slow sustained, concentrationdependent contractile response in equine cecal longitudinal muscle (Figure 6.2). The
carbachol-induced contractile effects were significantly greater than that induced by ET-1
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Figure 6.1 Physiograph recording (25 mm/sec) of cecal circular (A) and longitudinal (B)
smooth muscle spontaneous contractile responses, - - 2g tension.
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Figure 6.2 - Physiograph recording (25 mm/sec) of cecal longitudinal muscle contractile
response to increasing log molar concentrations of ET-1.

122

(Figure 6.3).Pre-incubation of cecal longitudinal muscle strips with the ETA receptor
antagonist, BQ-123, did not inhibit the contractile response of ET-1 (Figure 6.4). A slight
non-significant increase in contractile activity was observed in tissues pre-incubated with
BQ-123 (10-9, 10-7 M), compared with that of control tissues (P>0.05). Similarly, preincubation of tissues with the ETB receptor antagonist, IRL-1038, did not abolish ET-1
induced response (Figures 6.4 & 6.5). The contractile responses of longitudinal tissue to
ET-1 were significantly decreased when tissues were pre-incubated with BQ-123 and
IRL-1038 together at 10-5M concentrations, compared with tissues incubated with lower
dose of the both receptor antagonists (10-7, 10-9 M) and compared with control tissues
receiving no antagonists (Figure 6.6). Contractile activity of the longitudinal muscle
strips was not affected by EFS in both control tissues and those incubated with atropine
and guanethidine. Also, the addition of tetrodotoxin did not alter the contractile activity
of cecal longitudinal smooth muscle.
6.5 Discussion

This study demonstrated that ET-1 causes a concentration-dependent contraction
of longitudinal smooth muscle of the equine cecum. The response of longitudinal smooth
muscle to ET-1 was significantly less than with the muscarinic agonist, carbachol, on an
equimolar concentration basis. It appears that the magnitude of ET-1 induced contractile
response is of lesser magnitude in intestinal smooth muscle compared to that of ET-1
effect in the large intestinal vasculature of horses (Venugopal et al., 2001). Preincubation of longitudinal muscle strips with the ET antagonists, BQ-123 and IRL-1038,
at any concentration did not cause a significant reduction in the response induced by ET1. However, when tissues were pre-incubated with both antagonists together, the
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Figure 6.3- Mean ± SEM % change in area under the curve (AUC) in equine longitudinal
smooth muscle to log molar concentrations of endothelin-1 and carbachol. *Significant
differences (P<0.0001) in response for ET-1 and carbachol were observed at log molar
concentrations of 10-7 M and 10-6 M.
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ET A Antagonist Study
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Figure 6.4 - Mean ± SEM % change in area under the curve (AUC) in equine
longitudinal smooth muscle to log molar concentrations of endothelin-1 before (control)
and after incubation of tissues with different log molar concentrations (10-9 M, 10-7 M and
10-5 M,) of an endothelin receptor-A antagonist (BQ-123).
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ET B Antagonist Study
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Figure 6.5 - Mean ± SEM % change in area under the curve (AUC) in equine
longitudinal smooth muscle to log molar concentrations of endothelin-1 before (control)
and after incubation with different log molar concentrations (10-9 M, 10-7 M and 10-5 M)
of an endothelin receptor-B antagonist (IRL-1038).
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ET A + ET B Antagonist study
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Figure 6.6 - Mean ± SEM percentage change AUC in equine longitudinal smooth muscle
to log molar concentrations of endothelin-1 before (control) and after incubation with
different log molar concentrations (10-9 M, 10-7 M and 10-5 M) of an endothelin receptorA and B antagonist (BQ-123 and IRL-1038) together. Contractile responses to ET-1 were
*significantly decreased when tissues were incubated with both antagonists at 10-5 M log
molar concentration (P <0.001).
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contractile effects of ET-1 were significantly inhibited. These findings suggest that both
endothelin receptors, ETA and ETB, mediate contraction in response to ET-1 in the cecal
longitudinal smooth muscle.
Along with branches of both autonomic nervous systems, intestinal peristalsis is
coordinated and controlled by the enteric nervous system (Van Hoogmoed et al., 2000).
The shortening and constricting movements of the equine cecum occur by the
synchronized contractions of circular and longitudinal smooth muscle, occurring
approximately every 4 minutes (Sellers and Lowe, 1986). Any lack of coordination
between activities of the smooth muscle layers can result in motility dysfunction.
Endothelin-1 is the most potent vasoconstrictor known to date, and its effect on intestinal
muscle varies depending on the type of tissue, section of the gastrointestinal tract and
species tested (Borges et al., 1989; Bolger et al., 1992; Takahashi et al., 1990; Eglen et
al., 1989). The ET-1 mediated contraction depends on the release of both intracellular
calcium and the entry of extracellular calcium (Yoshinaga et al., 1992). Both ETA and
ETB receptors are involved in the activation of gastrointestinal motility in guinea pig
ileum (Miasiro et al., 1995). Elevated plasma endothelin-1 like immunoreactivity has
been implicated with intestinal dysmotility in human patients with acute pancreatitis
(Chen et al., 1999). However, no studies have reported the role of ET-1 in intestinal
motility or dysmotility of horses.
Endothelins are found in enteric neurons with binding sites in the myenteric and
submucosal plexus, mucosa, muscular layers and in the vasculature of rat colon
(Takahashi et al., 1990). Endothelin receptors have the greatest distribution in cecum and
stomach, compared with other sections of the guinea pig intestine (Kuwahara et al.,
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2000). In the gastrointestinal tract, the contractile effect of ET-1 has been reported in the
guinea pig ileum (Bolger et al., 1992; Ishida et al., 1989) and the stomach and colon of
rats (Takahashi et al., 1990). Endothelin-1 causes a marked biphasic response in guinea
pig ileal longitudinal smooth muscle with a similar magnitude to that observed in
vascular smooth muscle (Lin and Lee, 1990; Miasiro et al., 1999). Okabe et al. (1995)
reported direct contractile effect of ET-1 in both longitudinal and circular smooth muscle
cells. In our study, ET-1 caused a slow, sustained concentration-dependent contractile
response (10-9 M to 10-6 M). The concentrations tested for ET-1, may or may not of
physiological concentration range, however, various neurotransmitters are found in
macromolar concentration. Also the degree of contraction of longitudinal smooth muscle
to ET-1 was significantly lower compared with that of muscarinic agonist, carbachol. The
contractile response of ET-1 in longitudinal smooth muscle was lower than the reported
effect of ET-1 in the colonic vasculature of horses (Venugopal et al., 2001). This
difference in the magnitude of the contractile response of ET-1 between vascular and
non-vascular smooth muscle has been documented in other species (Fulginiti et al.,
1993), suggesting that ET-1 has more potent contractile effects in vascular smooth
muscle than in intestinal smooth muscle.
Endothelin-1 has been implicated in regulation of gastrointestinal motility and in
the pathogenesis of ischemia and ischemia-reperfusion (I-R) injury (Tekin et al., 1999;
Anadol et al., 1998). Treatment with bosentan (ETB receptor antagonist) abolished I-R
injury induced intestinal transit delay suggesting that I-R associated delays in intestinal
transit involve an endothelin-dependent mechanism (Alican et al., 1998). Also, a
beneficial effect of ETA antagonists in reducing ET-1 induced gastric and intestinal
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mucosal damage in rats has been reported (Massberg et al., 1998). The ET antagonists
BQ-123 and IRL-1038 used in our study are specific competitive endothelin receptor
antagonists that block ETA and ETB receptors, respectively. In our study, the epithelial
mucosal and submucosal layer of the cecal tissues was removed for evaluating ET-1
response in the longitudinal smooth muscle. The ET receptors present in the muscular
layer of gastrointestinal smooth muscle are ETA and ETB2 receptor types, and both
mediate contractile response on binding to ET-1.
Pre-incubation of tissues with ETA receptor antagonist, BQ-123 (10-9 M, 10-7M,
10-5 M) did not significantly alter the ET-1 induced contractile response. However, the
contractile responses were slightly reduced on tissues pre-incubated with ETA receptor
antagonist at 10-5 M though it was not significantly different from other treatments
(Figure 6.4). Also the contractile response of ET-1 was slightly greater in tissues treated
with 10-7 and 10-9 M compared to control. No significant difference in contractile
response to ET-1 was seen in tissues pre-incubated with ETB receptor antagonist, IRL1038 at any concentration (Figure 6.5). Thus, pre-incubation of tissues separately with
BQ-123 and IRL-1038 did not significantly alter the ET-1 induced changes in cecal
longitudinal muscle tension. The contractile response to ET-1 was completely abolished
when tissues were incubated with both antagonists combined at 10-5 M concentration.
This type of response may be explained by the fact that when one receptor type is
blocked (ETA) the other receptor (ETB2) effects are unmasked to induce a contractile
effect, and vice versa. This could also suggest that both ETA and ETB receptors mediate
contraction of cecal longitudinal smooth muscle when ET-1 binds. Similarly, studies
using an ETA receptor antagonist (BQ 123) and a combined ETA / ETB receptor
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antagonist (PD145065) showed that both endothelin ETA and ETB2 receptor types
mediate contraction in the guinea pig ileum (Miasiro et al., 1995).
Under our experimental conditions, the contractile activity of the cecal
longitudinal smooth muscle layer was unaffected with EFS. Similarly, unlike in circular
smooth muscle, the contractile activity of the ventral colon longitudinal muscle strips of
horses was unaffected by EFS (Van Hoogmoed et al., 2000). The lack of EFS response in
our study can be speculated to be due either an insufficient release of neurotransmitter to
elicit a response or the effects of neurotransmitters were not sufficient to override the
intrinsic contractile (spontaneous contraction) responses.
In summary, ET-1 caused a concentration-dependent contractile effect on cecal
longitudinal smooth muscle of clinically healthy horses, which appears to be mediated by
both ETA and ETB receptors. However, the ET-1 induced contraction in cecal
longitudinal smooth muscle was not as pronounced as observed in equine vascular
smooth muscle and was less than carbachol-treated cecal smooth muscle. The observed
effects of ET-1 on cecal longitudinal smooth muscle contraction may suggest that
alterations in cecal motility might be associated with changes in ET-1 synthesis and
release during naturally acquired gastrointestinal tract disorders. Further studies are
needed to determine the role of ET-1 in the smooth muscle responses of diseased or
affected tissues.
6.6 Product Information
a

Beuthanasia-D, Schering-Plough Animal Health Corp, Union, NJ.

b

Endothelin-1, American Peptide Company, Sunnyvale, Calif.

131

c

BQ-123, American Peptide Company, Sunnyvale, Calif.

d

IRL-1038, American Peptide Company, Sunnyvale, Calif.

e

Carbachol, Sigma-Aldrich Inc, St Louis, Mo.

f

Atropine, Sigma-Aldrich Inc, St Louis, Mo.

g

Guanathedine, Sigma-Aldrich Inc, St Louis, Mo.

h

Tetrodotoxin, Sigma-Aldrich Inc, St Louis, Mo.

i

Model 7D polygraph, Grass instruments, Quincy, Mass.

j

Chart recorder model 25-60, Grass instruments, Quincy, Mass.

k

Grass S48 stimulator, Astro-Med Inc, Grass Instruments Division, West Warwick, RI.

k

Sigma Scan Pro 4.0, Jandel Scientific Software, San Rafael, Calif.

l

SAS for windows 95, version 7.0, SAS Systems Inc, Cary, NC.

6.7 References

Alican I, Yegen C, Olcay A, et al. Ischemia-reperfusion induced delay in intestinal
transit. Role of endothelins. Digestion 1998;59(4):343-348.
Allcock GH, Battistini B, Fournier A, et al. Characterization of endothelin receptors
mediating mechanical responses to the endothelins in the isolated stomach strip of the rat.
J Pharmacol Exp Ther 1995; 275(1):120-126.
Anadol AZ, Bayram O, Dursun A, et al. Role of endogenous endothelin peptides in
intestinal ischemia-reperfusion injury in rats. Prostaglandins Leukot Essent Fatty Acids
1998;59(4):279-283.
Blikslager AT, Bowman KF, Levine JF, et al. Evaluation of factors associated with
postoperative ileus in horses: 31 cases (1990-1992). J Am Vet Med Assoc 1994;205
(12):1748-1752.
Bolger GT, Liard F, Garneau M, et al. Characterization of intestinal smooth muscle
responses and binding sites for endothelin. Can J Physiol Pharmacol 1992;70(3):377384.
Bolger GT, Liard F, Krogsurd R, et al. Tissue specificity of endothelin binding sites. J
Cardiovasc Pharmacol 1990;16(3):367-375.

132

Borges R, Von Grafenstein H, Knight DE. Tissue selectivity of endothelin. Eur J
Pharmacol 1989;165:223-230.
Chakder S, Rattan S. Mechanisms and sites of action of endothelins 1 and 2 on the
opossum internal anal sphincter smooth muscle tone in vitro. J Pharmacol Exp Ther
1999; 288(1):239-246.
Chen CY, Lu CL, Chang FY, et al. Endothelin-1 is a candidate mediating intestinal
dysmotility in patients with acute pancreatitis. Dig Dis Sci 1999;44(5):922-926.
Clozel M, Gray GA, Breu V, et al. The endothelin ETB receptor mediates both
vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;
31;186(2):867-873.
Coceani F, Kelsey L, Seidlitz E. Evidence for an effector role of endothelin in closure of
the ductus arteriosus at birth. Can J Physiol Pharmacol 1992;70(7):1061-104
Eglen RM, Michel AD, Sharif NA, et al. The pharmacological properties of the peptide,
endothelin. Br J Pharmacol 1989;97(4):1297-1307.
Fulginiti J III, Cohen MM, Moreland RS. Endothelin differentially affects rat gastric
longitudinal and circular smooth muscle. J Pharmacol Exp Ther 1993;265(3):1413-1420.
Inagaki H, Bishop AE, Escrig C, et al. Localization of endothelin-like immunoreactivity
and endothelin binding sites in human colon. Gastroenterology 1991;101(1):47-54.
Ishida N, Tsujioka K, Tomoi M, et al. Differential activities of two distinct endothelin
family peptides on ileum and coronary artery. FEBS Letters 1989;247:337-340.
Kuwahara K, Kitsukawa Y, Suzuki Y, et al. Effects of several endothelin receptor
antagonists on gastrointestinal transit of guinea pigs. Dig Dis Sci 2000;45(5):960-966.
Lin WW, Lee CY. Biphasic effects of endothelin in the guinea-pig ileum. Eur J
Pharmacol 1990;176(1):57-62.
Malone ED, Kannan MS, Brown DR, et al. Adrenergic, cholinergic, and nonadrenergicnoncholinergic intrinsic innervation of the jejunum in horses. Am J Vet Res
1999;60(7):898-904.
Massberg S, Boros M, Leiderer R, et al. Endothelin (ET)-1 induced mucosal damage in
the rat small intestine: Role of ETA receptors. Shock 1998;9(3):177-183.
Miasiro N, Karaki H, Matsuda Y, et al. Effects of endothelin ETB receptor agonists and
antagonists on the biphasic response in the ileum. Eur J Pharmacol 1999;369(2):205213.

133

Miasiro N, Karaki H, Paiva C. Heterogeneous endothelin receptors mediate relaxation
and contraction in the guinea-pig ileum. Eur J Pharmacol 1995;285(3):247-254.
Okabe H, Chijiiwa Y, Yoshinaga M, et al. Direct contractile effect of endothelin-1 on
isolated circular smooth muscle cells of guinea pig caecum. Digestion 1995;56(1):21-24.
Rakestraw PC, Snyder JR, Woliner MJ, et al. Involvement of nitric oxide in inhibitory
neuromuscular transmission in equine jejunum. Am J Vet Res 1996; 57(8):1206-1213.
Reid AM, Titchen, DA. Gastric electromyographic activity in the milk-fed lamb. J
Physiol 1988;396:25-39.
Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry,
pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
Sellers AF, Lowe JE. Review of large intestinal motility and mechanisms of impactions
in the horse. Equine Vet J 1986;18:261-263.
Shahbazian A, Holzer P. Regulation of guinea pig intestinal peristalsis by endogenous
endothelin acting at ETB receptors. Gastroenterology 2000;119(1):80-88.
Takahashi K, Jones PM, Kanse SM, et al. Endothelin in the gastrointestinal tract:
presence of endothelin-like immunoreactivity, endothelin-1 messenger RNA, endothelin
receptors and pharmacological effect. Gastroenterology 1990;99(6):1660-1667.
Tekin E, Taneri F, Ersoy E, et al. Ileal and colonic contractions by endothelin-1 in
experimentally induced paralytic ileus in rats. Gen Pharmacol 1999;32(6):631-635.
Van Hoogmoed LM, Rakestraw PC, Snyder JR, et al. Evaluation of nitric oxide as an
inhibitory neurotransmitter in the equine ventral colon. Am J Vet Res 2000;61(1):64-68.
Venkova K, Krier J. A nitric oxide and prostaglandin-dependent component of NANC
off-contractions in cat colon. Am J Physiol 1994;266:G40-G47.
Venugopal CS, Holmes EP, Koch CE, et al. In vitro pharmacologic effect of two
endothelin-1 antagonists on equine colonic arteries and veins. Am J Vet Res 2001;
62(2):154-159.
Yoshinaga M, Chijiiwa Y, Misawa T, et al. Endothelin-B receptor on guinea pig small
intestinal smooth muscle cells. Am J Physiol 1992;262:G308-G311.

134

CHAPTER 7
DISSERTATION SUMMARY
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Endothelin-1, the most potent vasoconstrictor known to date, has been implicated
in a variety of physiological processes ranging from maintenance of vasomotor tone, ion
secretion, closure of the patent ductus arteriosus and control of gastrointestinal tract
motility. Also, ET-1 has been found to play a major role in the pathophysiology of
intestinal ischemia, cerebral vasospasm, peritonitis, megacolon and cardiogenic shock.
The maintenance of vascular tone and smooth muscle homeostasis is achieved mainly by
ET-1 in conjunction with NO. An imbalance in the release of ET-1 and NO are believed
to cause alterations in vasomotor tone and gastrointestinal motility. We investigated the
role of ET-1 in the gastrointestinal tract of horses by measuring circulating concentrations
of plasma ET-like immunoreactivity and characterized the role of ET-1 mediated
responses in equine cecal longitudinal smooth muscle. Endothelin-1 gene expression was
determined in different sections of the gastrointestinal tract of clinically healthy horses.
We examined the regional distribution of ET-1 like immunoreactivity using
immunohistochemical staining in the gastrointestinal tract of clinically healthy horses and
compared this to intestinal segments collected from horses with acquired strangulation
obstruction.
In the first study, we found increased concentrations of plasma ET-like
immunoreactivity in horses with acquired gastrointestinal disorders, compared with
clinically healthy horses. Median plasma concentrations of ET-like immunoreactivity
were 1.80 pg/ml (range, 1.09 to 3.2 pg/ml) in healthy horses. Plasma ET-like
immunoreactivity was greatest in horses with strangulating large intestinal obstruction
(median, 10.02pg/ml; range, 3.8 to 22.62 pg/ml), peritonitis (9.19pg/ml; 7.89 to 25.83
pg/ml), and enterocolitis (8.89 pg/ml, 6.30 to 18.36 pg/ml). Also, the concentration of
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ET-like immunoreactivity was significantly associated with survival, PCV, and duration
of signs of pain. The source of measured ET-like immunoreactivity in plasma remains
unclear. The increased circulating concentrations levels of ET-1 may be from the
damaged endothelium, from affected tissues or may be a result of hemoconcentration in
affected horses. Greater than 80% of the ET-1 synthesized by the endothelium is secreted
abluminally toward the tunica media where it functions in a paracrine fashion. Therefore,
measurement of plasma ET-1 concentrations may not truly reflect the overall synthesis
and release of ET-1 during pathophysiologic events. However, the significant increase in
ET-1 like immunoreactivity in severe intestinal disorders such as strangulating
obstruction and peritonitis, compared with other less severe disorders, indicates a
potential involvement of ET-1 in these disorders.
Immunohistochemical studies revealed regional distribution of ET-1 like
immunoreactivity in different segments of the equine gastrointestinal tract extending
from the duodenum to the right dorsal colon. The ET-1 like staining is confined to the
cytoplasm of the surface epithelium, villi, the muscular layer, and less intense staining in
the epithelial crypts. The endothelial lining of the blood vessels stained with veins stained
more intensely than arteries. The presence of ET-1 in the surface epithelial cells suggests
the potential physiological role of ET-1 in ion secretion and intestinal motility. This
function of ET-1 has previously been shown in rat and human colon. This is the first
study to report the presence of ET-1 in the gastrointestinal tract of horses. An increase in
the intensity of ET-1 staining from intestinal segments from horses with acquired small
intestinal and large colon strangulation obstruction, compared with intestinal segments
from healthy horses, was observed.
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We identified ET-1 gene expression in various sections of the gastrointestinal
tract of the clinically healthy horse, suggesting a role of ET-1 in the regulation of
intestinal function. Therefore, the intestinal segments may be a source of ET-1 synthesis
and release during gastrointestinal tract disorders as observed in our previous study.
Studies showing the presence of ET-1 and the correlation with other findings in various
disease conditions justifies the need to perform further studies such as in situ
hybridization and quantitative studies to determine the differential expression of ET-1 in
acquired gastrointestinal tract disorders of horses.
We characterized the role ET-1 mediated responses in equine cecal longitudinal
smooth muscle in vitro. Despite the dose-dependent increase in contractile activity of ET1 in spontaneously contracting equine longitudinal smooth muscle, the magnitude was
much less compared with the muscarinic agonist, carbachol. The effects of ET-1 on
intestinal smooth muscle occur by binding of ET-1 to its specific ET receptors types, ETA
and ETB. Binding of ET-1 to ETA in smooth muscle, and ETB in vascular endothelium
mediate contraction and dilatation, respectively. However, these responses vary
depending upon the tissues and species tested. Incubation of cecal longitudinal muscle
separately with BQ-123 (ETA blocker) or IRL-1038 (ETB blocker) did not significantly
inhibit the contractile activity to ET-1 at any concentration (10-9M, 10-7M, 10-5M).
However, contractile responses of cecal longitudinal smooth muscle to ET-1 were
significantly inhibited when tissues were incubated simultaneously with both antagonists
at a concentration of 10-5M (P<0.001). This suggests that both receptors ETA and ETB
receptors are likely involved in the contractile effect. The results from this study suggest
the presence of ETA and ETB receptors in the gastrointestinal tract and that they likely

138

mediate the contractile effect of ET-1 in cecal smooth muscle of horses. However,
findings from these studies do not explain the importance of ET-1 in intestinal motility
disorders, which will require further evaluation in affected intestinal segments.
In summary, the circulating concentrations of plasma ET-l may be a potential
indicator of severity of the gastrointestinal tract disorders in horses. Endothelin-1 gene
expression was detected in different sections of intestine including the duodenum,
jejunum, ileum, pelvic flexure and colon; as well as in the heart and lung.
Immunohistochemical localization of ET-1 like immunoreactivity in the surface
epithelium, villi and blood vessels in various segments of intestinal tract of healthy horses
and those with intestinal strangulation obstruction indicates its potential role in intestinal
secretions and motility. In horses, both ETA and ETB receptors mediate the ET-1 induced
contractile response in cecal longitudinal smooth muscle. Further investigation is
warranted to further characterize the role of ET-1 in the gastrointestinal tract of horses
during health and disease. Additionally, the benefit of ET antagonists in attenuating
motility disturbances and other disorders involving the intestinal vascular and
nonvascular smooth muscle of horses to be evaluated.
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